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Chapter 1: Initial Diagnosis 
 
Statement 1.1. ECCO-ESGAR Diagnostics GL (2018) 
A single reference standard for the diagnosis of Crohn’s disease (CD) or ulcerative colitis 
(UC) does not exist. The diagnosis of CD or UC is based on a combination of clinical, 
biochemical, stool, endoscopic, cross-sectional imaging, and histological investigations 
[EL5] 
 
A single reference standard for the diagnosis of Crohn’s disease (CD) or ulcerative colitis (UC) 
does not exist. At a minimum, the diagnosis of CD or UC is based on a combination of clinical, 
biochemical, stool, endoscopic, and histological investigations. When CD is suspected, it may 
be necessary to visualise (radiologically) the small intestine. Infectious colitis, including 
Clostridium difficile, should be excluded.  
 
Statement 1.2. ECCO-ESGAR Diagnostics GL (2018) 
Genetic or serological testing is currently not recommended for routine diagnosis of CD or 
UC [EL3]  
 
Statement 1.3. ECCO-ESGAR Diagnostics GL (2018)  
On diagnosis, complimentary investigations should focus on markers of disease activity 
[EL2], malnutrition, or malabsorption [EL5]. Immunization status should be assessed. 
Consider screening for latent tuberculosis [EL5] 
 
Statement 1.4. ECCO-ESGAR Diagnostics GL (2018)  
(ECCO Anaemia Guideline: statement 1D in Dignass et al.) 
Diagnostic criteria for iron deficiency depend on the level of inflammation. In patients 
without clinical, endoscopic, or biochemical evidence of active disease, serum ferritin <30 
μg/L is an appropriate criterion [EL2]. In the presence of inflammation, serum ferritin up to 
100 μg/L may still be consistent with iron deficiency [EL4] 
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Statement 1.5. ECCO-ESGAR Diagnostics GL (2018)  
(ECCO Anaemia Guideline: statement 1E in Dignass et al.) 
In the presence of biochemical or clinical evidence of inflammation, the diagnostic criteria 
for anaemia of chronic disease are serum ferritin >100 μg/L and transferrin saturation <20%. 
If the serum ferritin level is between 30 and 100 μg/L, a combination of true iron deficiency 
and anaemia of chronic disease is likely [EL2] 
 
At diagnosis, every patient should have a biochemical assessment with full blood count, 
inflammatory markers (C-reactive protein [CRP]), electrolytes, liver enzymes, and a stool 
sample for microbiological analysis, including C difficile. [1, 2]. The full blood count may reveal 
thrombocytosis (due to an inflammatory response), anaemia, and leucocytosis. The presence 
of raised inflammatory markers (CRP) broadly correlates with clinical severity in CD [1] but 
less so in UC except in the case of acute severe colitis in UC [2]. However, laboratory markers 
of chronic inflammation may be normal in both UC and CD [3, 4]. As raised CRP, leucocytosis, 
or both are not IBD-specific, their presence cannot differentiate IBD from infectious (or other 
causes of) colitis. Apart from biochemical evidence of malnutrition, hypoalbuminaemia can 
reflect severe inflammation; however this is not superior to CRP [4].  
 
One of the most frequent complications of IBD is anaemia (haemoglobin [Hb] <13 g/dL for 
men and <12 g/dL for women), which may affect patients’ quality of life and should hence be 
evaluated at initial diagnosis [5-7]. In case of documented anaemia, further workup should 
start from the evaluation of mean corpuscular volume (MCV). Microcytic anaemia is usually 
the most common type of anaemia in IBD, which usually indicates iron-deficiency anaemia 
[8]. Macrocytosis may indicate vitamin B12 or folate deficiency, whereas normocytosis may 
suggest anaemia of chronic disease (ACD) [9]. The distinction between iron deficiency 
anaemia and ACD is important as treatment is different between these conditions. 
 
The diagnosis of iron deficiency depends on the level of inflammation. In patients without 
clinical, endoscopic, or biochemical evidence of active disease, the diagnosis is made when 
serum ferritin is <30 µg/L [10, 11]. In the presence of inflammation, serum ferritin up to 100 
µg/L may still be compatible with iron deficiency [12, 13]. Other markers suggestive of iron 
deficiency anaemia are low MCV, raised red cell distribution width (RDW), microcytic 
hypochromic pencil red cells on blood film, low serum iron, raised total iron-binding capacity, 
and transferrin saturation of <16% [14].  
 
Faecal calprotectin (FC), a neutrophil-derived protein, appears to be the most sensitive 
marker of intestinal inflammation in IBD. Other neutrophil-derived proteins are elastase, 
lysozyme, and lactoferrin [3, 15-20]. Calprotectin values correlate well with endoscopic 
indices of disease activity and are thus important in various clinical settings, including initial 
diagnosis, diagnosis of relapse, and response to treatment [21-25].  
 
In the initial investigations of a patient with gastrointestinal symptoms, an ileocolonoscopy 
should be performed in the presence of a raised stool marker. An exact cut-off value that 
distinguishes between IBD and functional bowel diseases has yet to be determined [26, 27]. 
However, good diagnostic accuracy can potentially be obtained at a cut-off value of 150 µg/g, 
as recently suggested in a meta-analysis [28]. However, FC lacks the specificity to discriminate 
between IBD and other causes of intestinal inflammation (17).  
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During the diagnostic process of IBD, gastrointestinal infections should always be excluded [1, 
2]. Loose stools for more than 6 weeks usually discriminate IBD-associated colitis from most 
cases of infectious diarrhoea [29]. Stool specimens should be obtained to exclude common 
pathogens and specifically assayed for C difficile toxin. Additional tests may be tailored 
according to medical history, such as those who have travelled abroad. This may include the 
assessment for ova, cysts, and parasites [30].  
 
Serologic markers may be used to support a diagnosis, though the accuracy of the best 
available tests (pANCA and ASCAs) is rather limited and hence ineffective at differentiating 
colonic CD from UC [31, 32]. Similarly, the additional diagnostic value of anti-glycan and 
antimicrobial antibodies such as anti-OmpC and CBir1 is small [3, 4, 33, 34]. Likewise, although 
242 IBD-associated susceptibility SNPs have been identified, genetic testing for common 
variants does not allow diagnosis of IBD [35]. 
 
Some infections are preventable and the risk for severe infections during immunosuppression 
can be decreased or eliminated if the patient is adequately vaccinated. Vaccination is best 
given before initiating immunomodulatory therapy. The following should be assessed as 
necessary before vaccination: hepatitis B surface antibody, hepatitis B antigen, hepatitis B 
core antibody, hepatitis A IgG, measles serology, and varicella serology. Additional baseline 
tests recommended at diagnosis include hepatitis C serology, Epstein-Barr serology and 
human immunodeficiency virus serology, after appropriate counselling [36]. 
 
Statement 1.6. ECCO-ESGAR Diagnostics GL (2018) 
For suspected IBD, ileocolonoscopy with biopsies from inflamed and uninflamed segments 
are required to establish diagnosis [EL1], except in the case of acute severe colitis in which 
sigmoidoscopy may be sufficient [EL3] 
 
Statement 1.7. ECCO-ESGAR Diagnostics GL (2018) 
No endoscopic feature is specific for CD or UC. The most useful endoscopic features of UC 
are considered to be continuous and confluent colonic involvement with clear demarcation 
of inflammation and rectal involvement [EL2]. The most useful endoscopic features in CD 
are discontinuous lesions, presence of strictures and fistulas, and perianal involvement 
[EL2] 
 
For a reliable diagnosis of UC and CD, ileocolonoscopy with a minimum of two biopsies from 
the inflamed regions should be obtained [37-40]. Additional biopsies from uninflamed regions 
and every colonic segment (including the rectum, especially in UC) may be helpful in the 
diagnostic process and to diagnose microscopic pathology. The distinction of infectious colitis 
from IBD is usually characterised by preserved crypt architecture and acute inflammation 
[41]. Other differential diagnoses include segmental colitis associated with diverticulitis 
(SCAD) and ischaemic colitis [42-45].  
 
Granulomas and focal crypt architectural abnormalities, in conjunction with focal or patchy 
chronic inflammation (defined by the presence of lymphocytes and plasma cells), or mucin 
preservation at active sites are CD-related histological features. The patchy nature of the 
inflammation is only diagnostic in untreated adult patients [46-50]. One single feature is not 
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considered to be diagnostic, though there are no data available as to how many features must 
be present in an endoscopically derived biopsy before a firm diagnosis can be made [40]. On 
surgical samples, a diagnosis of CD should be made when at least three histological features 
suggestive of CD (segmental crypt architectural abnormalities and mucin depletion, mucin 
preservation at the active sites, and focal chronic inflammation without crypt atrophy) are 
present in the absence of granulomas, or when an epithelioid granuloma is present with one 
other feature [39, 40]. 
 
Focal or diffuse basal plasmacytosis has been recognized as the earliest feature with the 
highest predictive value for UC diagnosis. This can be identified in 38% of patients within 2 
weeks after symptom presentation. During this period, the distribution pattern of basal 
plasmacytosis is focal but may eventually change into a diffuse pattern throughout the 
disease course.  Only about 20% of patients show crypt distortion within 2 weeks of the first 
symptoms of colitis. The distinction from infectious colitis is therefore a major concern. 
Widespread mucosal or crypt architectural distortion, mucosal atrophy, and an irregular or 
villous mucosal surface appear later, at least 4 weeks after presentation [41, 51]. Not all 
microscopic features found in UC are observed in early disease. A correct diagnosis of UC is 
reached in approximately 75% of cases where two or three features are present. However, 
the exact number of features needed for UC diagnosis has not been established [37]. 
 
Due to the increased risk of bowel perforation, complete ileocolonoscopy is not usually 
recommended in case of acute severe colitis [52]. However, a study by Terheggen et al. 
demonstrated that there was no relationship between complication rate and disease activity 
[53]. 
 
Flexible sigmoidoscopy can be safely performed to establish the diagnosis of UC. Phosphate 
enema preparation before flexible sigmoidoscopy has been reported to be safe in this setting 
[54], though it is generally advised to avoid purgatives, especially fleet enemas and oral 
sodium phosphate preparations [55]. 
 
Statement 1.8. ECCO-ESGAR Diagnostics GL (2018) 
Patients with clinical suspicion of CD and with normal endoscopy should be considered for 
small-bowel capsule endoscopy (SBCE) evaluation or cross-sectional imaging [EL2]. If 
stenotic disease is suspected, risk of retention should be assessed [EL2] 
 
Small-bowel capsule endoscopy (SBCE) is a sensitive tool to detect mucosal abnormalities in 
the small bowel. There are currently two validated indexes available, namely the Capsule 
Endoscopy Crohn’s Disease Activity Index (CECDAI) and the Lewis score, which assess the 
disease location and activity of small bowel involvement. Both will be discussed further in this 
guideline. The diagnostic yield of SBCE is comparable to other modalities (MR enterography, 
small intestine contrast ultrasound [SICUS]), apart from proximal small bowel involvement for 
which SBEC seems superior [56]. As proximal small bowel involvement is associated with a 
higher risk of surgery [57], this superior accuracy might have prognostic value [56]. Data from 
small, prospective cohorts suggest that the diagnostic yield of SBCE is highest in patients with 
suggestive CD symptoms and increased inflammatory markers [58, 59], although this was not 
replicated in larger retrospective cohorts [60, 61]. However, the likelihood of positive 
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diagnosis is very low in patients with suspected CD with FC <50 μg/g [62]. Additionally, all 
patients with unclassified IBD at diagnosis could also be considered for SBCE.  
 
Similarly, as normal radiological tests of the small bowel cannot entirely exclude small-bowel 
involvement, CD patients with normal radiological tests can be considered for additional 
SBCE. Contraindications for SBCE include gastrointestinal obstruction, strictures, and 
swallowing disorders [63-65]. The risk of capsule retention in patients with suspected CD 
without obstructive symptoms and without history of small bowel resection or known 
stenosis is low and comparable to that of obscure GI bleeding [66-69]. Data on retention rates 
in patients with CD varies from 2 to 13% in patients with established CD to approximately 
1.5% in patients with suspected CD [70]. If small-bowel stenosis is not firmly excluded, a 
patency capsule can be used to confirm small bowel patency before performing SBCE. All 
patency capsules are dissolved within 72 hours. SBCE is considered safe if the patency capsule 
is excreted before 30 hours, an intact capsule is excreted after 30 hours, or passage to the 
colon of an intact patency capsule has been radiologically confirmed [71]. Yadav et al. 
demonstrated that the negative predictive value (NPV) for patency capsules and radiological 
tests were not significantly different [72]. Thus, if either test is negative before SBCE, the 
patient will most likely pass the capsule without incident. Radiological tests have the 
advantage of eliminating false positive results, as they do not depend on intestinal motility. 
However, cross-sectional imaging is significantly less accurate in the evaluation of functional 
small-bowel patency, frequently overestimating the risk of obstruction. In a recent study 
evaluating the accuracy of MRI for prediction of patency capsule retention in patients with 
established small-bowel CD, the sensitivity and specificity of MR enterography were 92.3% 
and 59%, respectively. Thus, if the decision to administer SBCE was based on imaging and not 
patency capsule results, at least 40 % of the patients would not have undergone SBCE [57]. 
Questions about optimal bowel preparation, selection of patients, and the optimal reading 
protocol remain to be clarified [73] and are discussed in more detail later in this guideline. 
 
Statement 1.9. ECCO-ESGAR Diagnostics GL (2018) 
Upper GI endoscopy is recommended in patients with CD with upper GI symptoms but not 
for asymptomatic newly diagnosed adult IBD patients [EL5] 
 
CD involving the upper GI tract (oesophagus, stomach, and duodenum) is almost invariably 
accompanied by small or large bowel involvement [74-76]. Patients who have upper 
gastrointestinal symptoms such as nausea, dyspepsia, and vomiting will benefit from upper 
GI endoscopy [77].  Whether asymptomatic adult CD patients should routinely undergo 
oesophago-gastroduodenoscopy is still debated. However, a prospective registry reported a 
higher prevalence of upper GI involvement in asymptomatic CD patients than initially 
expected [77], suggesting a place for a standard gastroscopy at CD diagnosis to correctly 
evaluate disease extent. When it is difficult to obtain a histological diagnosis of CD, upper GI 
endoscopy may support the diagnosis, as focal gastritis may be a feature of CD [74]. 
 
Additionally, a minority of UC patients may also have upper GI tract inflammation, manifesting 
as diffuse duodenitis or gastritis characterized by oedema, erythema, erosions, and thickened 
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mucosal folds. Finally, upper GI endoscopy is mandatory in patients with suspected 
concomitant coeliac disease [78]. 
 
The sensitivity and specificity of radiological imaging techniques in the assessment of upper 
GI CD is unclear, with publications limited to case reports and small series. Radiological 
assessment of patients should be reserved only for those patients with CD and upper GI 
symptoms in whom endoscopic assessment has failed or is incomplete. Radiological 
assessment of the upper GI tract should not form part of routine diagnostic workup.   
 
 
Statement 1.10. ECCO-ESGAR Diagnostics GL (2018) 
All newly diagnosed CD patients should undergo small-bowel assessment (intestinal 
ultrasound, MR enterography, capsule endoscopy, or combinations thereof) [EL3]  
 
The ileocaecal region is usually visualized adequately endoscopically. The proximal ileum and 
jejunum can be more difficult to assess. A study by Samuel et al. evaluated CD patients with 
CT enterography and ileocolonoscopy. From the group of patients with normal results from 
ileoscopy, 53.7% of these patients had active, small-bowel CD. Ileoscopic examination can 
thus miss CD of the terminal ileum, as the disease can skip the distal ileum or is confined to 
the intramural portion of the bowel wall and mesentery [79].  
 
CT and MRI are both used as to assess the small intestine. Both techniques can establish 
disease extent and activity based on wall thickness and increased intravenous contrast 
enhancement [80]. A direct comparison of CT and MRI for the diagnosis of a variety of small 
intestinal lesions demonstrates high sensitivity and specificity, similar for both techniques 
[81-83]. Due to the absence of radiation, MRI should be preferred over CT particularly in 
young patients [81].  
 
A study by Messaris et al. demonstrated that routine use of MR enterography can alter the 
management of patients with ileal or ileocolonic CD. In this study, 53% of patients had 
additional medical management for active inflammation and 16% underwent an operation 
for complicated CD or medical intractability. The intraoperative findings were consistent with 
the MRI diagnosis in all surgically treated patients [84]. Similarly, Mendoza et al. 
demonstrated that MRI influenced a change in treatment (medical or surgical) in 55.3% of 
patients. The change in management even affected those patients who were already 
diagnosed with ileal or ileocolonic CD [85].  
 
A direct comparison of intestinal ultrasound (IUS) and MRI performed in 234 consecutive 
suspected CD patients showed a similar diagnostic accuracy in detecting small-bowel CD. 
Sensitivity, specificity, positive predictive value (PPV), and NPV for CD diagnosis were 94%, 
97%, 97%, and 94% for IUS and 96%, 94%, 94%, and 96% for MR enterography, respectively. 
IUS was less accurate than MR enterography in defining CD extent (r=0.69), whereas the 
concordance in terms of CD location between the two procedures was high (κ=0.81). MR 
enterography also showed a fair concordance with IUS regarding strictures (κ=0.82) and 
abscesses (κ=0.88), with better detection of enteroenteric fistulas (κ=0.67) [86]. 
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A review by Calabrese et al. reported that IUS had a 79.7% sensitivity and 96.7% specificity 
for the diagnosis of suspected CD and an 89% sensitivity and 94.3% specificity in assessment 
of patients with known CD with lower accuracy for detecting proximal small-bowel lesions. 
Administration of an oral contrast agent improved the sensitivity and specificity in 
determining CD lesions [87].  
 
In a systematic review, the diagnostic yield of SBCE is comparable to MR enterography and 
IUS, apart from proximal small-bowel involvement for which SBCE seems to be superior. The 
odds ratio (OR) for diagnosis via SBCE versus MR enterography was 0.56 (95% confidence 
interval [CI] 0.28–1.13; P=0.1) and the OR for SBCE had superior diagnostic yield for proximal 
small-bowel disease with an OR of 2.62 (95% CI 1.10–6.53; P=0.03) [56]. 
 
A range of factors, including local availability and expertise, determines the choice of small-
bowel imaging modality. For initial assessment and exclusion of CD, SBCE, IUS, MR 
enterography, and CT enterography are superior to small-bowel follow through (SBFT) [83, 
88]. Cross-sectional imaging of the small bowel should be performed with preference for SBCE 
where clinical symptoms indicate obstructive or stricturing small-bowel CD. 
 
 
Statement 1.11.  ECCO-ESGAR Diagnostics GL (2018) 
The presence of at least three small-intestine ulcers in SBCE highly suggests a diagnosis of 
CD, provided the patient has not been using NSAIDS for at least one month before the test 
[EL4] 
 
Statement 1.12. ECCO-ESGAR Diagnostics GL (2018) 
In patients with negative endoscopy and suspicion of CD on MRI or small-bowel capsule 
endoscopy, device-assisted enteroscopy may be performed if diagnosis needs to be 
confirmed endoscopically and histologically [EL3] 
 
Several small studies have evaluated the utility of SBCE for reclassification of patients with UC 
and with unclassified IBD and reported varying reclassification rates. Although a normal SBCE 
cannot exclude CD, the presence of small-bowel pathology that is consistent with CD enables 
reclassification [89-94]. In a study by Mow et al., multiple ulcerations (≥3 ulcerations) were 
considered diagnostic for CD and were observed in 26% of cases [89]. Similar data have been 
reported by Monteiro et al.; 25% of patients with unclassified IBD were found to have small-
bowel involvement consistent with CD. Still, 37% of patients remained IBD unclassified during 
further follow up [94]. 
 
Statement 1.13. ECCO-ESGAR Diagnostics GL (2018) 
Patients with unexplained perianal abscesses or complex fistulas should be investigated for 
CD [EL4] 
 
Perianal manifestations result in fistula and abscess formation in 21 to 54% of CD patients 
[95-98] and more frequently (up to 41%) in patients with isolated colonic involvement 
compared with isolated ileal disease (12%) [96]. A thorough baseline clinical examination of 
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the perianal area should to be performed in all newly diagnosed patients at ileocolonoscopy, 
as symptoms can be initially very mild.  
 
Diagnosis and classification of perianal disease is usually achieved via a combination of both 
clinical and imaging findings [99]. Fistulas can be considered ‘simple’ if they are low (of 
superficial or low intersphincteric or low transsphincteric origin), have a single external 
opening, and lack evidence of abscesses, rectovaginal fistulas, or anorectal strictures. 
‘Complex’ fistulas are high (of high intersphincteric or high transsphincteric or 
extrasphincteric or suprasphincteric origin), may have multiple external openings, and can be 
associated with the presence of abscesses, rectovaginal fistulas, or anorectal strictures [100]. 
 
A perianal abscess may be the first presentation of CD in a healthy individual [101]. Patients 
with an unexplained fistula and suspicion of CD should therefore undergo ileocolonoscopy to 
assess mucosal inflammation in the ileum or colon that may indicate CD [102]. In case of a 
negative conventional workup including ileocolonoscopy, capsule endoscopy can provide an 
incremental diagnostic yield of 24% [103].  
 
Proctosigmoidoscopy or ileocolonoscopy (if the proximal colon also needs evaluation) should 
be performed routinely in all patients with perianal CD to assess disease extent, severity of 
luminal inflammation, presence of internal openings, and to exclude complications such as 
strictures and cancer [102, 104]. Proctitis is a known risk factor of persistent non-healing 
fistula tracts and increased proctectomy rates [105] and often indicates complex fistulae and 
associated complications such as abscesses [99]. Undiagnosed extensions and abscesses are 
major causes of recurrent disease after attempted surgical cure [99]. 
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Chapter 2: Monitoring known IBD 
 
2.1. Monitoring therapeutic success 
 
Statement 2.1.1.1. ECCO-ESGAR Diagnostics GL (2018) 
Response to treatment in active ulcerative colitis (UC) should be determined by a 
combination of clinical parameters, endoscopy, and laboratory markers such as C-reactive 
protein (CRP) and calprotectin [EL1] 
 
Statement 2.1.1.2. ECCO-ESGAR Diagnostics GL (2018) 
In patients with UC who clinically respond to medical therapy, mucosal healing (MH) should 
be determined endoscopically or by faecal calprotectin (FC) approximately 3 to 6 months 
after treatment initiation [EL5] 
 
Statement 2.1.1.3. ECCO-ESGAR Diagnostics GL (2018) 
Endoscopic reassessment in UC should be considered in case of severe relapse, persistent 
disease activity, new unexplained symptoms, and prior to switch of therapy [EL5]. 
Sigmoidoscopy might be sufficient in most patients [EL5] 
 
There is no gold standard in determination of therapeutic success in ulcerative colitis (UC). 
For follow up of active disease in UC, endoscopy remains the reference standard. As UC 
involves the mucosa continuously from the rectum, colonoscopy with biopsies is still the 
reference standard for assessment of disease extent. However, flexible sigmoidoscopy is 
adequate for assessment of disease activity in most patients.  
 
Several studies determined the benefit of mucosal healing (MH) in patients with UC. In a 
prospective Norwegian cohort, MH was associated with reduced risk of colectomy in UC and 
lower inﬂammation at 5 years [106]. These findings could be conﬁrmed by a recent meta-
analysis [107]. In accordance with these ﬁndings, an international consensus panel recently 
recommended MH as an important therapeutic goal for UC [108]. 
 
There is no evidence-based consensus of when best to reassess disease activity after a change 
in therapy. However, in most induction studies MH has been determined approximately 2 to 
3 months after starting treatment [109]. Although this appears to be an appropriate time 
point to reassess, the exact timing will depend upon clinical necessity and therapy.  
 
There is a growing need to replace invasive diagnostics by surrogate noninvasive markers. 
Blood parameters are convenient. However, C-reactive protein (CRP) has low sensitivity in 
determining active mucosal disease in UC, with serum levels frequently within normal limits 
even in active disease [110]. The exception is in patients with elevated CRP levels during 
disease flare, for whom CRP might be used as a suitable follow up. A more accurate surrogate 
marker of MH is faecal calprotectin (FC). There is a strong correlation between endoscopic 
inflammation and FC in UC. In a study with 52 patients, FC correlated with clinical Mayo score 
(r=0.63; P<0.0001) [111]. This correlation was strengthened by adding the endoscopic 
subscore (r=0.90; P<0.0001). The endoscopic subscore also correlated independently with FC 
(r=0.96; P<0.0001). The use of FC as a surrogate marker for MH in UC has also been 
demonstrated in several other studies [112, 113]. 
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Another potential noninvasive alternative for monitoring active UC is intestinal ultrasound 
(IUS). In four studies that assessed the diagnostic accuracy of IUS in a total of 74 patients, 
sensitivities ranged from 48 to 100% and specificities ranged from 82 to 90%. Current 
evidence indicates that the diagnostic accuracy of IUS in UC is also related to disease site, as 
sensitivity is high for sigmoid or descending colonic disease (reaching 97%) [114] but low for 
rectal disease [115]. The utility of IUS for assessing activity has been assessed in a study 
including 38 IBD patients (12 UC) and 6 controls [116]. The mean colonic wall thickness was 
3.2 mm in both Crohn’s disease (CD) and UC, being higher in moderately (n=46; P<0.001) or 
severely inflamed bowels (n=20; P<0.001) compared with normal segments (n=58). There are 
only few studies that address the use of IUS for follow up of patients with active UC under 
treatment. In a recent study of 83 patients with moderate-to-severe UC, endoscopic and IUS 
severity was graded 0 to 3 at entry according to validated scores [115]. Of the recruited 
patients, 74 patients who were clinically responsive to steroids were followed up with 
repeated colonoscopy and IUS at 3, 9, and 15 months from recruitment. A high and consistent 
concordance was demonstrated between endoscopic and IUS scores (weighted κ between 
0.76 and 0.90). Thus, IUS may be a potential alternative to endoscopy to assess response to 
treatment of severe UC.  
 
As IUS has significant limitations in detecting rectal disease, proctitis cannot be followed by 
IUS as an alternative to sigmoidoscopy. While FC has been shown to be useful for follow up 
of proctitis during treatment with mesalamine suppositories 8 weeks after treatment, the 
absolute levels of FC in ulcerative proctitis are low [117]. Transrectal endosonography studies 
show that mucosal thickness correlates with endoscopic disease activity and a decline in 
bowel wall thickness, which can be determined a few weeks after treatment in patients with 
active UC [118].  
 
No study has compared the combination of different parameters such as IUS plus FC in active 
UC, even though it is conceivable that combinations might enhance sensitivity. MR 
colonography (MRC) can also assess inflammation with relatively high accuracy. In the largest 
series of 50 patients who underwent both MRC and endoscopy, the segmental simplified MRC 
index strongly correlated with the modified Baron score (r=0.81, P<0.001). MRC was also able 
to detect endoscopic inflammation and severe lesions with high diagnostic accuracy 
(sensitivity 87% and 83%, specificity 88% and 82%, area under the curve 0.95 and 0.91, 
P<0.001, respectively). MRI may provide useful information on wall thickening, oedema, 
polyps, and extraluminal complications [119-121]. MRI, especially when implemented with 
diffusion-weighted sequences, has high diagnostic accuracy in detecting active inflammation. 
Oussalah et al. investigated 35 patients with UC and reported a sensitivity and specificity of 
89.47% and 86.67%, respectively [122]. Moreover, the accuracy of the diffusion-weighted 
imaging hyperintensity for detecting colonic inflammation was greater in UC than in CD 
(P=0.004).  
Statement 2.1.2.1. ECCO-ESGAR Diagnostics GL (2018) 
Clinical and biochemical response to treatment of Crohn’s disease (CD) should be 
determined within 12 weeks following initiation of therapy [EL2]. Endoscopic or transmural 
response to therapy should be evaluated within 6 months following initiation of therapy 
[EL5] 
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Statement 2.1.2.2. ECCO-ESGAR Diagnostics GL (2018) 
Endoscopic or cross-sectional reassessment in CD should be considered in cases of relapse, 
persistent disease activity, new unexplained symptoms, and prior to switch of therapy [EL5]  
 
Mucosal healing 
There is no reference standard for determining therapeutic success in CD. Clinical symptoms 
as scored by the CD activity index (CDAI) are not a reliable measure of the underlying 
inflammation. An increasing body of evidence suggests that MH may change the natural 
course of CD by decreasing relapse rates, hospitalization rates, and the need for surgery [123-
125]; as such evaluation should be aimed at detecting this endpoint, or at least assessing a 
reliable surrogate marker of MH. MH can be directly visualized endoscopically. Cross-
sectional imaging and noninvasive serological and faecal surrogate markers may however 
provide an indication, especially important when assessing parts of the bowel that are difficult 
to reach endoscopically.    
 
The time interval of when to evaluate MH endoscopically can be inferred somewhat from trial 
data. However, studies have seldom been designed to directly evaluate the best point for 
reassessment, and as such inferences regarding optimal timing for re-evaluation must be 
taken with care. Any recent change in therapy must also be considered. For example, it is 
recognized that the anti-integrin antibody vedolizumab takes longer than steroids or anti-
TNFs for MH to occur. A sub-study of the SONIC trial demonstrated that MH along with 
steroid-free clinical remission at week 26 was strongly predictive of steroid-free clinical 
remission at week 50 (82%) [126]. The EXTEND trial demonstrated that MH at 12 weeks 
correlated well with MH at 52 weeks [125]. Thus, it appears that 12 to 24 weeks is a sensible 
timescale for re-evaluation of MH.  
 
The degree of mucosal inflammation may differ between segments of the digestive tract 
[127]; the need for panenteric evaluation remains to be determined. Whether noninvasive 
markers (such as CRP) or faecal markers (such as FC) might replace endoscopy in assessment 
of treatment success has been determined in several studies. In a retrospective analysis of 
the SONIC trial, CDAI scores and CRP values at baseline and at week 26 were analysed from 
188 CD patients who had evaluable ileocolonoscopy with evidence of mucosal ulceration at 
baseline [128]. Half of the patients treated with azathioprine or infliximab (or both) in clinical 
remission had endoscopic or CRP evidence (or both) of residual active CD, whereas other 
patients with endoscopic and CRP normalization had persistent clinical symptoms. In a 
retrospective study of 201 patients with CD, the predictors of medium-term clinical efficacy 
and MH during adalimumab therapy were evaluated [129]. Thus, correlation between CRP 
and MH is variable. Several studies indicate that FC correlates well with colonic inflammation 
in CD and might therefore be used as a surrogate marker [62, 111]. Importantly, although 
initial studies suggested that FC may be less sensitive in isolated small-bowel disease, a recent 
meta-analysis demonstrated that the diagnostic yield of FC is significant for detection of active 
disease in the small bowel, with a negative predictive value (NPV) of 90% for the cut-off value 
of 50 µg/mL [62]. 
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Transmural healing – Role of MRI, CT, and IUS 
 
There is no reference standard for IBD activity and any kind of diagnostic modality (including 
endoscopy, MRI, laboratory parameters, or IUS) can only be used as surrogate markers in this 
situation. CD is a transmural process, thus full-thickness small-bowel healing or remodelling 
could be important endpoints.  
 
Various studies have assessed the value of cross-sectional imaging techniques for therapeutic 
monitoring in CD affecting the small and large bowel. These studies assessed IUS [130-135], 
CT [136], or MRI [137-139].  
 
The utility of IUS for assessing activity and drug response has been compared with 
colonoscopy [115], with high concordance (weighted κ between 0.76 and 0.90). The role of 
IUS as a noninvasive and inexpensive imaging modality for determining the treatment 
response of transmural inflammation in CD has been evaluated in different studies. A 
prospective IUS study was performed on 15 patients with CD using contrast-enhanced 
ultrasound (CEUS) to assess changes mediated by anti-inflammatory treatment and its 
relationship with clinical and biological response [140]. The parameters were measured 
before and after 6 months of anti-inflammatory treatment. In 13 patients, the slope of the 
enhancement curve and the area under the enhancement curve were significantly lower after 
anti-inflammatory treatment (P<0.05), with a significant correlation with CDAI score (r=0.85; 
P<0.05). Another prospective study performed on 24 consecutive patients with CD used IUS 
to assess changes induced by anti-TNF therapy and its relationship with clinical and biological 
response [141]. Parameters were measured one week prior to induction treatment and two 
weeks thereafter. Anti-TNF therapy led to a significant reduction in bowel wall thickness 
(P=0.005) and Doppler flow (P=0.02), leading to the disappearance of IUS changes in 50% of 
the patients. However, sonographic normality was only achieved in five out of 17 patients 
(29%) with a clinical and biological response and could not differentiate between those with 
and without clinical and biological response (P=0.27). A study with 24 patients used IUS to 
assess bowel wall thickness and vascularization after treatment with anti-TNF therapy [141]. 
In this trial, anti-TNF therapy led to a significant reduction in bowel wall thickness and in 
vascularization as determined by Doppler flow. Ultrasound parameters showed improvement 
in 50% of the patients in this trial. A more recent prospective trial evaluated IUS features in 
patients with CD after treatment with biologicals using ileocolonoscopy as a reference 
standard [142]. In this trial, normalization of the IUS parameters could be observed in 62.8% 
of the patients, with a significant correlation compared to ileocolonoscopy (κ=0.76; P<0.001). 
Some authors suggest that CEUS might be useful to determine treatment outcome shortly 
after initiating treatment with biologicals [132]. In a study on 133 CD patients, transmural 
healing could be observed in approximately 25% of patients [133]. Most of the patients 
received anti-TNF therapy. In a paediatric CD study, 32 patients were included and followed 
up by IUS and ileocolonoscopy 9 to 12 months after treatment initiation. Patients with MH 
showed a significant decrease of bowel wall thickness and disease extension at T1 (4.3±1.4 
mm and 8±6.3 cm versus 6.1±2.3 mm and 13±5 cm at baseline, respectively; P<0.001) [134]. 
Complete transmural healing was achieved in 14% of patients; all of these patients showed 
complete MH. In a prospective multicentre longitudinal study of 51 patients with active CD, 
all patients underwent a clinical assessment and sonographic examination at baseline, 12 
weeks after treatment initiation, and after 1 year of treatment [135]. Improvement at 52 
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weeks was more frequent in patients with improvement at the end of induction (12 weeks) 
compared with patients who did not improve (85% versus 28%; P<0.0001). The authors 
concluded that sonographic response after 12 weeks of therapy predicts 1-year sonographic 
response. 
 
A large multicentre trial including 243 patients from 50 centres in Germany has recently been 
conducted to determine the role of IUS for monitoring treatment response [131]. In this trial, 
CD patients with an acute disease flare received anti-inflammatory treatment. Most of these 
patients had been treated with anti-TNF therapy and had a significant drop in Harvey-
Bradshaw index scores after 3 months. Almost all sonographic parameters determined during 
IUS (including bowel wall thickness, vascularization parameters, fibro-fatty proliferation, and 
other parameters) showed a highly significant decrease (P<0.001 in all groups) at different 
sites. Interestingly, reduction of bowel wall thickness was more pronounced in the colon 
compared with the ileum in this study. Improvement of ultrasound parameters correlated 
with laboratory parameters such as CRP [131]. These data demonstrate that ultrasonography 
is indeed a very useful method for follow up of patients with CD and to determine early 
therapeutic responses. Based on current studies, IUS seems to be a valuable method to 
determine transmural healing in CD [143]. It appears that the most relevant parameters that 
should be monitored during IUS are bowel wall thickness and vascularization. 
 
The value of CT was assessed in a retrospective North American study on 63 infliximab-treated 
patients with CD [136]. Twenty-one of 105 lesions (20%) were colonic. Poor-to-fair correlation 
was found between CT enterography features of response and improved clinical symptoms (κ 
0.26), improved endoscopic appearance (κ 0.07), and reduction of CRP (κ 0.30). When 
comparing responders (complete and partial) with nonresponders, only the presence of the 
‘comb sign’ on the index CT enterography was predictive of radiologic response (P=0.024). 
Even though CT in principle might be a suitable method to determine disease activity in CD, it 
should be noted that CT, due to radiation safety, should not usually be used for monitoring 
disease activity if MRI or IUS are available. 
 
In terms of responsiveness and reliability, different studies have shown that MRI has a high 
accuracy for monitoring therapeutic responses using endoscopy as a reference standard [137-
139]. In a recent study, 48 patients with ileocolonic CD were prospectively evaluated with MR 
enterography in comparison with ileocolonoscopy [137]. MR enterography determined ulcer 
healing with 90% accuracy and endoscopic remission with 83% accuracy. The mean CD 
endoscopic index of severity (CDEIS) and magnetic resonance index of activity (MaRIA) scores 
significantly changed at week 12 in segments with ulcer healing, based on endoscopic 
examination (CDEIS, 21.28±9.10 at baseline versus 2.73±4.12 at 12 weeks; P<0.001 and 
MaRIA, 18.86±9.50 at baseline versus 8.73±5.88 at 12 weeks; P<0.001). The authors 
concluded that the MaRIA score is a valid, responsive, and reliable index assessing response 
to therapy in patients with CD.  
 
As MR enterography and IUS appear to be of similar value for monitoring transmural healing 
in CD during treatment, which imaging modality to use depends on local availability and 
expertise. 
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Video-capsule endoscopy 
 
As endoscopic access of the small bowel is more difficult, response to treatment should either 
be determined by IUS or MR enterography or by capsule endoscopy. The superiority of small-
bowel capsule endoscopy (SBCE) compared with other imaging modalities to determine 
small-bowel disease in CD has been described in different studies [144]. 
 
Recent clinical trials have evaluated the potential role of SBCE for assessment of MH in the 
small bowel [145-147]. These trials used quantitative scores such as the Lewis score [148] or 
the capsule endoscopy CD activity index (CECDAI) analogous to the application to 
ileocolonoscopy of the CDEIS or the simple endoscopic score for CD. In a case-control study, 
40 patients with known or suspected CD were included and underwent SBCE [145]. When 
patients achieved clinical response (after at least a month of treatment) they underwent a 
second SBCE, with evaluation of the same parameters. The numbers (mean±SEM) of large 
ulcers before and after treatment were 8.3±1.4 and 5±0.8, respectively (mean difference 
3.3±1.2, 95% confidence interval [CI] 0.8–5.9; P=0.01). The other two variables did not 
improve significantly. In another study, the CECDAI index was used to assess ileitis severity. 
All parameters were reassessed at week 52. In total, 108 capsule procedures were performed 
on 43 patients. Based on the CECDAI, 39 patients (90%) exhibited active small-bowel CD at 
baseline with 28 patients (65%) undergoing assessment at 52 weeks. In total, 12 patients 
(42%) achieved complete MH and deep remission at the 52-week assessment (95% CI -0.62 
to -0.22; P<0.0001) [146]. SBCE has a significant impact on disease management; in the largest 
retrospective series of patients with established CD that were evaluated with SBCE, a change 
in management was suggested in 52% of 187 patients [60].  
 
 
Statement 2.1.2.3. ECCO-ESGAR Diagnostics GL (2018) 
In the absence of credible evidence to support the best modality to assess response to 
treatment in upper GI disease of CD, endoscopy is recommended as the preferred method 
[EL5]. 
 
Data on imaging in upper GI CD and in particular on monitoring disease is sparse and sizeable 
series are unavailable, with essentially absent data for the stomach. Cross-sectional imaging 
may reveal ulcers or strictures in oesophageal CD but superficial lesions are difficult to detect, 
underscoring the importance of endoscopy in the diagnosis of oesophageal CD. Endoscopy 
with tissue biopsy is useful to exclude other common oesophageal disorders. The most 
commonly described findings on endoscopy include aphthous ulcers, superficial erosions, and 
late-stage stricture development and cobblestoning of the mucosa [149, 150]. One study 
discussed the application of various methods to diagnose various inflammatory conditions of 
the oesophagus [151]. 
 
Although IUS and MRI seem to be feasible tools to determine disease activity of CD in the 
duodenum and stomach, there are no convincing data that prove their value in disease 
monitoring. Upper GI involvement should therefore be primarily monitored by the reference 
standard endoscopy.  
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Statement 2.1.2.4. ECCO-ESGAR Diagnostics GL (2018) 
Extramural complications in CD (such as fistulae and abscesses) should be monitored by 
cross-sectional imaging, including intestinal ultrasound (IUS) [EL2] or MRI [EL2] (or both) in 
combination with clinical and laboratory parameters [EL5]  
 
While a variety of studies have shown good sensitivity and specificity of cross-sectional 
imaging to assess fistulae and abscesses, there are only few studies that address the follow 
up of these extramural complications after treatment. The sensitivity of cross-sectional 
imaging modalities such as MRI, IUS, and CT to determine extramural complications has been 
shown to be high in a recent meta-analysis, with sensitivity between 84 to 93% and specificity 
between 90 to 93%, as discussed above [81, 152]. Although CT is accurate for follow up of 
mural and extramural complications in CD patients, CT is not recommended for monitoring 
patients with active disease under treatment due to radiation safety [153]. Although the dose 
can be reduced substantially with state-of-the-art low-radiation-dose CT scanners, the use of 
nonionizing radiation techniques is preferable, considering the usually young age of these 
patients. Thus, CT should be used judiciously, ideally only in the emergency setting and if IUS 
and MRI are unavailable. 
 
Statement 2.1.2.5. ECCO-ESGAR Diagnostics GL (2018) 
Perianal CD should be reassessed by clinical evaluation in combination with endoscopic 
examination of the rectum plus MRI [EL1]. Transrectal ultrasonography (TRUS) in the 
absence of anal stenosis [EL1] or transperineal ultrasonography (TPUS) [EL2] might be used 
instead of MRI 
 
Evaluation of perianal CD and fistula closure is primarily achieved with clinical evaluation. The 
definition of fistula healing varies in the literature and there is no consensus on when a first 
or definitive evaluation of fistula healing should be performed [154]. The perianal disease 
activity index (PDAI) [155] is a clinical scoring system that has been used and validated in 
clinical studies both at diagnosis and to measure treatment response. Fistula drainage 
assessment has been used in several clinical trials of medical therapy [156-158], but is very 
much investigator-dependent and has not been validated in large studies. A single 
retrospective study has evaluated the PDAI scoring system, where high scores predicted 
short-term surgical outcome, but this has not since been validated [159].  
 
MRI classifications of fistula severity have been proposed, such as the system published by 
Van Assche et al. [160]. Thus far, this system is of limited use outside of clinical trials. MRI is 
increasingly used to assess fistula healing, particularly during medical therapies [160-162]. 
Various MRI classifications have been proposed, including the Van Assche score [160], which 
considers the number of fistulae, localization, extensions, T2 hyperintensity, abscesses, and 
rectal involvement. Assessment of dynamic contrast enhancement has also been proposed as 
a means to monitor fistula activity [163]. It has been shown that fistulae may reopen after 
therapy cessation and studies using MRI findings as a more stringent endpoint of deep fistula 
healing suggest that MRI [160, 162, 164] and endoanal ultrasound [165, 166] may be useful 
for identification of fistulae that show external closure but retain an internal fistula tract. This 
suggests that imaging assessment of deep healing is superior to simple clinical evaluation, 
although long-term comparative studies are lacking.  
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Despite the lack of relevant studies evaluating the role of MRI for the specific assessment of 
patients during and after therapy, several comparative studies have been performed 
evaluating ultrasound and MRI in perianal fistula diagnosis in CD. In most of these studies, 
MRI seems to be the method of choice. Schwartz et al. compared examination under 
anaesthesia (EUA), MRI, and transrectal ultrasonography (TRUS) and demonstrated a 
diagnostic accuracy of 91%, 87%, and 91%, respectively [167]. Buchanan et al. performed a 
large prospective clinical trial comparing preoperative digital rectal examination, endoscopic 
ultrasound and body-coil MRI for the preoperative assessment of fistulae in ano. According 
to their results, MRI was superior to both methods for abscess detection and accuracy in 
fistula classification (90% of patients correctly classified by MRI, 81% by TRUS, and 61% by 
EUA) [168]. In a recent meta-analysis, the sensitivity between MRI and TRUS regarding 
sensitivity to determine perianal CD was 87% for both imaging modalities, while specificity 
was 69% versus 43%, respectively [169]. A recent consensus suggested a combination of 
different imaging modalities for diagnostic use during perianal CD [170].   
 
MRI may therefore be slightly superior to TRUS for determining perianal disease activity. 
However, use of the adequate imaging modality also depends on local availability and 
expertise. 
 
If MRI is not available and TRUS is either not available or unfeasible due to pain, transperineal 
ultrasonography (TPUS) is an alternative, although its sensitivity is lower than TRUS. In a 
recent study investigating 46 patients with perianal CD, 53 fistulae detected by TRUS were 
correctly classified by TPUS in 45 cases, reaching a sensitivity of 84.9% [171]. 
 
 
Statement 2.1.2.6. ECCO-ESGAR Diagnostics GL (2018) 
Therapeutic drug monitoring might be beneficial in CD and UC in patients with nonresponse 
to thiopurines [EL3] or anti-TNF therapy [EL2]. Drug level monitoring is mandatory during 
treatment with calcineurin inhibitors [EL2]  
 
Primary nonresponse and secondary loss of response are common problems during anti-TNF 
therapy. Loss of response (LOR) to anti-TNF has been shown to be as high as 20 to 40% after 
the first year of treatment [172] and about 10% in the following years. 
 
In a recent study on 247 patients, it was shown that therapeutic drug monitoring by 
measurement of anti-TNF trough levels and antidrug antibodies in IBD patients with 
secondary LOR may lead to therapeutic changes in more than 70% of patients [173]. Several 
studies have demonstrated that low trough levels and detectable antidrug antibodies are 
associated with LOR [174-176]. In a recent meta-analysis of 22 trials with 3483 patients, it 
was shown that high infliximab trough levels correlate with good clinical response and low 
CRP levels [177]. Similar results have been shown for golimumab [178] and adalimumab [179]. 
Even though the primary endpoint of the TAXIT trial (treatment guidance via infliximab trough 
level concentration measurements) was not achieved, it was shown that dose escalation in 
patients with subtherapeutic levels improved clinical response [180]. The optimal trough level 
concentration in this study was defined as between 3 to 7 µg/mL. A cohort of 60 CD patients 
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treated with adalimumab has been investigated retrospectively [181]. Higher adalimumab 
trough levels were significantly associated with MH (median 14.7 µg/mL in those with MH 
versus 3.4 µg/mL in those without; P<0.001). This study suggests that attaining MH alone or 
a combined outcome of clinical and endoscopic remission is more likely to occur in those 
patients who achieve an adalimumab trough level of at least 8.14 µg/mL. 
 
In a recent study, primary nonresponse to anti-TNF therapy in patients with severe UC was 
associated with faecal loss of infliximab [182]. However, the optimal timepoints and cut-off 
levels for trough level measurements to determine primary nonresponse must still be 
determined. 
 
Different studies have shown that measurement of thiopurine metabolites, such as 6-MMP 
and 6-TGN, might be beneficial in patients with suboptimal response to thiopurines. In a 
recent study, determination of 6-TGN and 6-MMP levels identified patients with reduced 
compliance in 11% and raised 6-MMP levels in 10%. Treatment improvement could be 
achieved in 87% of patients after optimizing thiopurine usage [183].  
 
It is likely that as vedolizumab and ustekinumab drug monitoring becomes more easily 
available, this will also form part of management strategies when treating patients with these 
agents.  
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2.2. Monitoring clinically asymptomatic patients 
 
Statement 2.2.1. ECCO-ESGAR Diagnostics GL (2018) 
In patients with IBD who have reached clinical and biochemical remission, monitoring is 
aimed at early recognition of a disease flare [EL5]. The interval of monitoring should be 
between 3 to 6 months depending upon duration of remission and current therapy [EL5].  
Relapse can be detected with FC before clinical symptoms [EL2] 
 
Figure 1 shows a simplified disease progression pathway in IBD from risk factors to irreversible 
intestinal fibrosis. Of note, the practicality of a given test for IBD monitoring decreases further 
downstream in the pathway, as the disease becomes more resistant to standard therapy.  
 
 
Figure 1. Targets along the disease progression pathway in IBD 
 
 
The ideal monitoring test is noninvasive, simple to conduct, and easily interpretable. Such a 
test should detect an imminent disease flare (often undetectable by symptom-based 
reporting alone) and make provision for proactive treatment optimization (Table 1).  
 
Faecal calprotectin 
The utility of FC monitoring in patients with quiescent disease was evaluated in a recently 
published systematic review [184]. Electronic searches up to April 2016 identified six 
prospective studies (mostly in UC patients) that met the selection criteria. Since then an 
additional five prospective studies in both UC and CD patients were published [117, 185-188].   
Two consecutively elevated FC levels were the best predictor for clinical relapse, but this was  
systematically investigated in only one study [189]. In one of the more recently published 
studies, patients with both UC and CD provided faecal samples every third month and were 
prospectively followed until the first clinical relapse [186]. This study revealed that FC levels 
start rising approximately 3 months before a relapse becomes clinically apparent and 
confirmed the observations of the aforementioned systematic review. These findings support 
the biological implausibility that a single FC measurement at baseline can predict the clinical 
course over a 12-month period, as suggested in a meta-analysis [190] and more recently by 
Theede et al. [191].  
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Currently, there is no consensus on the ideal cut-off point for FC monitoring. In clinical trials 
where response to a new treatment is monitored, a low cut-off point (e.g. 100 μg/g) is 
frequently used to demarcate the upper limit of the normal FC range. Conversely, in real-life 
studies, a higher cut-off point is advocated (e.g. 250 μg/g) as an action threshold for adjusting 
treatment [192-195]. A prospective evaluation of a monitoring strategy is needed, namely, a 
planned and organized system of repeated FC assessments and subsequent decisions about 
starting, modifying, or de-escalating therapy. The monitoring strategy as a whole should be 
seen as a new technology that merits formal evaluation. 
 
A general construct for FC-based disease monitoring in patients with IBD is shown in Figure 2, 
which illustrates the four phases of disease monitoring [196, 197]. Repeated FC measures are 
used to longitudinally track changes in a patient’s condition over time. In phase I, IBD is 
suspected, but neither endoscopically confirmed nor treated. In phase II, induction therapy is 
introduced to achieve disease control, resulting in patient response. Phase III begins with 
disease remission with continuation of maintenance therapy. The goal of monitoring in this 
phase is to detect deviations from the target range, indicating the start of phase IV. In phase 
IV, therapy is adjusted to re-establish disease control and bring FC levels back to the target 
range. 
 
 
Figure 2. Conceptual model of FC-based monitoring in IBD patients 
 
When the FC concentration is in the target range, the patient is reassured and advised to 
retest in 3 months. When the FC concentration is in the action range, the treatment plan is 
adjusted and retesting is advised for the next month. In the uncertain range, a test interval of 
1 month is advised before progressing to a treatment decision.  
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C-reactive protein 
Serum CRP is an acute-phase reactant that has been used in clinical practice for many years 
as a general measure of inflammation. In a meta-analysis of cohort and case-control studies 
that compared the diagnostic accuracy of CRP (index test) with endoscopy (reference 
standard) in patients with symptomatic IBD, a CRP concentration of ≥5 mg/L appeared to have 
a high specificity for detecting endoscopic disease activity [110]. However, the sensitivity was 
very poor and a negative test does not exclude the presence of a flare. Almost two thirds of 
the asymptomatic patients with normalized CRP still had active endoscopic lesions, and 
consequently an isolated fall in CRP was insufficient reassurance of endoscopic remission 
[198]. Repeated CRP measurements in the detection of early postoperative recurrence of CD 
[199] or in the follow up of small-bowel CD [200] are inferior to repeated FC measurements. 
 
Statement 2.2.2. ECCO-ESGAR Diagnostics GL (2018) 
Asymptomatic patients with abnormal biochemical parameters may have an imminent 
disease flare. After excluding infection, endoscopic or cross-sectional imaging (or both) 
should be performed [EL5] 
 
Capsule endoscopy 
Recent prospective studies have shown that stool markers such as FC are useful in monitoring 
inflammation in the small bowel. Increased FC levels with negative findings on conventional 
endoscopy should trigger further investigations into the presence of active small-bowel 
disease [201]. Small-bowel CD is in many cases located proximal to the terminal ileum and 
therefore inaccessible to conventional ileocolonoscopy. In a considerable proportion of 
asymptomatic patients with CD, previously unknown new proximal involvement and 
progression to stricturing  or penetrating disease was demonstrated with capsule endoscopy 
[61], leading to modifications in the original Montreal classification and consequently to 
treatment escalation [202]. In a prospective observational cohort of patients with 
asymptomatic or mildly active small-bowel CD, tolerance and preference to MR enterography 
versus capsule endoscopy were compared. Pre-examination and procedural discomfort was 
perceived more favourable in capsule endoscopy. The superior tolerability of capsule 
endoscopy, along with diagnostic features, should be considered when choosing between 
these two modalities for long-term follow up [203]. A negative FC result in an asymptomatic 
CD patient should deter the clinician from using additional small-bowel imaging techniques 
[201].  
 
MR enterography 
 
MR enterography is not a suitable technique for early recognition of disease recurrence, since 
aphthoid ulcerations cannot be assessed. As disease severity progresses, MR enterography 
manifestations become more apparent. Several studies have evaluated the ability of MR 
enterography to quantify therapeutic response to immunosuppressive therapy, especially in 
children [204].  
 
Intestinal ultrasound 
IUS is a noninvasive, widely available technique that does not use ionizing radiation and is 
well accepted and tolerated by patients. Most parts of the large bowel (with the exception of 
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the rectum) and major parts of the small bowel (with the exception of the proximal jejunum) 
can be visualized by IUS. The advantages of IUS include rapid evaluation of bowel wall 
thickness and direct visualization of bowel vascularization and motility [87, 205, 206]. The role 
of this technique in monitoring patients with asymptomatic CD or UC is not yet clear. More is 
known about the role of IUS in monitoring response to treatment in CD patients. In a 
prospective trial that followed 234 CD patients with bowel wall alterations in the terminal 
ileum or in the colon, follow-up every three month showed significant improvements in nearly 
all ultrasound parameters [131]. There is good concordance between ultrasound and MR 
enterography for disease location and activity, and fewer technical difficulties with IUS [207].  
 
Statement 2.2.3. ECCO-ESGAR Diagnostics GL (2018) 
Before de-escalation or withdrawal of maintenance IBD therapy, it is necessary to assess 
disease activity using a combination of clinical and biochemical markers and endoscopic or 
cross-sectional imaging (or both), balancing the risks and benefits of withdrawal [EL5]  
 
In a recent meta-analysis of 18 studies, stopping immunomodulatory monotherapy after a 
period of remission was associated with approximately 75% of patients experiencing a relapse 
within 5 years after therapy discontinuation [208]. Approximately 50% of patients who 
discontinued anti-TNF therapy after combination therapy in this systematic review 
maintained remission 24 months later, but the proportion decreased over time [208].  Similar 
results have been reported in other meta-analyses [209, 210]. The factors that predict relapse 
after discontinuation of therapy remain controversial. 
 
In a placebo-controlled study by the GETAID group that included 83 patients in clinical 
remission under azathioprine, neither the presence of ulcerations nor a CDEIS N 0 at 
ileocolonoscopy before azathioprine discontinuation were predictive of clinical relapse [211]. 
In contrast, in another recent GETAID trial, Louis et al. assessed the risk of clinical relapse after 
discontinuation of infliximab in 109 patients with CD who were in clinical remission under 
combined maintenance therapy with infliximab and an immunomodulatory agent [212]. In 
their multivariate analysis, the absence of MH (CDEIS N 0) was among the factors strongly 
associated with an increased risk of clinical relapse after infliximab withdrawal (hazard ratio 
2.6). In this study, immunosuppression with azathioprine or methotrexate was continued 
after infliximab withdrawal. In a recent meta-analysis, the relapse rate 1 year after 
discontinuation of anti-TNF therapy was 42%, which decreased to 26% when endoscopic 
remission was also required [209]. Assessment of endoscopic activity in patients with 
quiescent CD is recommended before discontinuation of treatment is considered.  
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Table 1. Markers of disease activity for monitoring asymptomatic IBD patients 
 
 Validity 
(correlation 
with gold 
standard) 
Responsiveness 
to changes in 
condition 
Signal-to-noise 
ratio (ability to 
differentiate 
changes in 
condition from 
background 
variability) 
Practicality 
Endoscopy Gold standard Gold standard Gold standard Low  
Requires bowel 
preparation 
and general 
anaesthesia in 
children  
Faecal 
calprotectin 
Good  Good 
Rises quickly in 
case of relapse; 
falls rapidly with 
successful 
treatment  
Moderate 
Risk of false 
positive results  
High 
Possible 
reluctance of 
patients for 
repeated stool 
collection  
C-reactive 
protein 
Moderate Moderate  
Late position in 
disease 
progression 
pathway  
Moderate 
Risk of false 
positive results 
(acute infections 
and other 
inflammatory 
conditions) and 
false negative 
results (normal 
CRP despite active 
disease)  
High  
Quick result; 
but requires 
venepuncture 
Capsule 
endoscopy  
Good Good 
 
Moderate 
Potential 
overinterpretation 
of insignificant 
mucosal lesions 
Moderate  
Requires bowel 
preparation, 
but is generally 
well tolerated 
MR 
enterography 
Moderate Moderate  
Late position in 
disease 
progression 
pathway 
Unknown Moderate 
Requires oral 
preparation for 
bowel 
distention and 
in children 
preparation 
through a 
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nasoduodenal 
tube 
Intestinal 
ultrasound 
Unknown Good Unknown High 
Noninvasive, 
widely 
available, and 
well tolerated 
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2.3 Monitoring clinically symptomatic patients  
 
Statement 2.3.1. ECCO-ESGAR Diagnostics GL (2018) 
All patients with a suspected new flare of IBD should be investigated for infection, 
including exclusion of Clostridium difficile infection [EL3]  
 
Bacterial infection and Clostridium difficile should be excluded in all patients. Diagnostic 
workup is recommended according to test availability and local practice. Available tests 
include glutamate dehydrogenase antigen and toxin A/B enzyme immunoassays, bacterial 
cultures, cytotoxicity assay, and nucleic acid amplification technology tests.  
 
This is particularly important in patients with colonic disease where the diagnostic yield is 
higher; in one series of paediatric patients with UC (N=354 stool tests), 1.8% of tests were 
positive for Salmonella serotype Typhi and 13.6% were positive for C difficile toxin [213]. 
Patients with CD have comparatively lower rates of C difficile infection [214].  
 
In UC, C difficile is associated with poorer outcome, including increased colectomy rates [215] 
and increased postoperative complications [216] [217]; detection is thus of direct clinical 
relevance. Additional interrogation of faeces with PCR should not be performed routinely as 
there is a high rate of detection of bacteria that may not be of clinical significance, even in 
healthy controls [218]. 
Parasitic infections are found in about 12% of patients with UC who reside in endemic areas 
[219]. If travel history is suggestive, stool examination for ova cysts and parasites and 
Strongyloides serology should be performed before therapy is escalated. Local protocols 
regarding testing and transport of stool samples should be followed. Further guidance on 
management of opportunistic infection can be found in the second European evidence-based 
consensus on the prevention, diagnosis, and management of opportunistic infections in 
inflammatory bowel disease [36]. 
 
Statement 2.3.2. ECCO-ESGAR Diagnostics GL (2018) 
Cytomegalovirus (CMV) should be tested in immunosuppressant-resistant UC as CMV is 
associated with adverse outcomes, including reduced efficacy of therapy and increased 
colectomy rates [EL3] 
 
A recent meta-analysis revealed that cytomegalovirus (CMV) infection in IBD may be 
associated with longer disease duration, reduced efficacy of corticosteroid therapy, and 
increased colectomy rate [220]. Corticosteroid and thiopurine exposure are associated with 
reactivation of latent CMV [221]. However, tissue damage following exposure to 
immunomodulators is rare [222]. Anti-TNF agents and cyclosporine also do not appear to be 
associated with adverse outcomes in CMV-positive patients [223]. Therefore, the ECCO 
guidance on opportunistic infections recommends that testing for CMV should be reserved 
for steroid-resistant disease [36]. 
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CMV disease is most commonly assessed via detection of CMV DNA through PCR of tissue 
biopsies and blood. The second European evidence-based consensus on opportunistic 
infection in IBD provides more detailed information on the diagnosis and management of 
CMV infection [36].  
 
Statement 2.3.3. ECCO-ESGAR Diagnostics GL (2018) 
Colonoscopy is the modality of choice to assess disease activity of symptomatic colonic CD 
or UC [EL5]. Cross-sectional imaging is complementary to assess phenotype [EL2] and may 
be used as an alternative to evaluate disease activity. Sigmoidoscopy should be 
considered in UC if symptoms suggest an acute severe flare 
 
Ileocolonoscopy provides direct mucosal visualization of the colon and terminal ileum and 
allows histological assessment and therapeutic intervention. As such it is the gold standard 
investigation of large-bowel disease.  
 
If assessment of disease location or behaviour is not necessary, FC can be used to evaluate 
activity from the colon to the small bowel [224],[225],[226],[201],[62],[227]. Studies have 
shown good correlation (r>0.8) with endoscopic disease activity in both CD and UC 
[228],[229]. 
 
If acute severe UC is suspected, endoscopic evaluation should be limited to flexible 
sigmoidoscopy as discussed previously in this guideline.  
 
MR enterography [230],[231],[232],[233],[234].[235] of the colon, capsule endoscopy 
[236],[237],[238], and IUS [114] can also be considered for assessment of disease extent and 
phenotype in individuals reluctant to endoscopic evaluation.   
 
 
Statement 2.3.4. ECCO-ESGAR Diagnostics GL (2018) 
Symptomatic small-bowel disease can be investigated with MR enterography, IUS, or 
small-bowel capsule endoscopy (SBCE) or combinations thereof [EL2] 
 
MR enterography, IUS, and SBCE are all sensitive and specific investigations of symptomatic 
small-bowel disease. The decision on which investigation is ‘first line’ is based upon local 
availability and expertise.  
 
MR enterography allows assessment of the small bowel without radiation exposure [239]. 
The presence of wall oedema, contraction frequency [240], ulcers, and extramural signs such 
as fat stranding and lymphadenopathy make MR enterography somewhat informative of 
whether the abnormalities detected are more inflammatory or fibrotic 
[241],[242],[243],[244]. However, it should be noted that no imaging modality can fully assess 
whether a stricture is inflammatory or fibrotic in nature. MR enterography is also safe and 
well tolerated in paediatric populations [245],[246],[247]. A recent meta-analysis of 27 
studies (19 included in pooled analysis) showed MRI to have a sensitivity of 0.88 (95% CI 0.86–
0.91) and a specificity of 0.88 (95% CI 0.84–0.91) [248]. The studies included both MR with 
oral contrast solution (MR enterography) or contrast administered by nasojejunal tube 
insertion (MR enteroclysis). MRI is perhaps superior to IUS in assessing disease extent [86] 
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and leads to changes in clinical management following investigation [249]; MRI increases 
scores of disease location (L) and disease behaviour (B) of the Montreal classification in over 
20% of patients [250].  
 
MR enteroclysis is not significantly more sensitive or specific than MR enterography [251]. 
MR enteroclysis is also less well tolerated than MR enterography [252] and requires minimal 
radiation exposure for fluoroscopic nasojejunal placement [253]. Accordingly, MR 
enteroclysis is not routinely recommended. 
 
IUS may be available immediately within the clinical setting; if this investigation is sufficient 
to confirm active disease it may preclude the need for further investigation. The sensitivity 
and specificity of IUS can be enhanced with contrast studies. Small intestine contrast 
ultrasound (SICUS) entails administering oral contrast and enables a greater rate of detection 
of small-bowel lesions than by standard IUS [254],[255] and in particular enables greater 
detection of strictures and associated dilatation. SICUS shows sensitivity and specificity 
comparable with MR enterography and CT enterography [256],[257],[258]. In one study, 
SICUS was shown to be more sensitive in the proximal small bowel (92% versus 75%), similar 
within the proximal and mid ileum, and less specific within the terminal ileum [259]. One 
study showed SICUS to be more sensitive and specific than CT enteroclysis [260]. The rates of 
detection of small-bowel complications (such as strictures) are comparable with MR 
enterography [257]. CEUS may facilitate differentiation between inflammatory and fibrotic 
strictures [261].  
 
Most studies show the diagnostic accuracy of SBCE to be comparable with MR enterography, 
CT enterography, and IUS in CD [262],[263],[264],[265],[56, 266], although a 2017 meta-
analysis demonstrated superior detection of proximal small-bowel disease compared with 
MR enterography (odds ratio [OR] 2.79, 95% CI 1.2–6.48) [56]. This is in comparison with MR 
enterography, CT enterography, barium studies, and IUS [88]. Clinically, the use of SBCE is 
associated with earlier escalation of therapy [267]. However, the benefits of this investigation 
are somewhat offset by a small risk of capsule retention; even with use of patency capsule in 
patients deemed to be at risk, the rates of capsule retention range from 1.5 to 2.1% [60]. The 
outcome of the retained capsule varies between studies; approximately 85% are 
asymptomatic and 15% result in partial or complete small-bowel obstruction. The latter 
generally requires surgical management. The former can sometimes be retrieved with small-
bowel enteroscopy or managed conservatively [268]. Routine use of a patency capsule has 
not been shown to reduce the risk of retention in the absence of risk factors. Patients who 
benefit from patency capsules include those with stricturing or penetrating disease 
phenotypes [269]. Cost analyses suggest that SBCE is cost effective [270] and frequently leads 
to changes in therapy [271].  
 
Barium studies, in particular barium follow through, are still used in some centres for 
suspected active small-bowel CD [272], [273]. However, sensitivity and specificity are less 
than that of MR enterography, IUS, or SBCE. Furthermore, radiation exposure also makes 
barium studies less appealing [274]. This is particularly true in paediatric assessment [275]. 
Accordingly, ECCO-ESGAR discourages barium studies unless local facilities preclude 
alternatives.  
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CT should largely be reserved for the emergency setting due to radiation exposure. However, 
low-radiation CT enterography yields results comparable with full-dose CT when evaluating 
CD. Accordingly, low-radiation CT enterography may be an alternative when local resources 
preclude alternatives or in older patients where radiation exposure is of less concern. When 
considering the efficacy of CT, the diagnostic yield of CT enterography is similar to that of MR 
enterography [276],[277],[80]. Indeed, several studies comment that CT yields images of 
higher spatial resolution [278],[279],[280] and that there is greater agreement between 
radiologists when interpreting CT [276]. CT is often the only cross-sectional abdominal 
imaging modality available outside of standard working hours and as such is widely used in 
the emergency setting. CT has a high detection rate of complications, including perforation, 
strictures, and abscesses [280].  
 
Studies of positron emission topography (PET) are limited. At present, PET does not appear 
to detect significantly more lesions than CT enterography [281] or MR enterography alone 
[282]. Leukocyte scintigraphy has been shown to detect inflammatory lesions not otherwise 
known prior to laparotomy. However, there is insufficient evidence to routinely include this 
test in clinical practice [283]. 
 
Noninvasive evaluation of symptomatic IBD includes measurement of blood and stool 
inflammatory markers and measurement of parameters indicative of malabsorption.  
The use of noninvasive markers to assess disease activity is largely covered elsewhere. In 
brief, FC is a more sensitive marker of disease activity than haemoglobin, CRP, or albumin 
[284],[285]. In symptomatic disease, FC can be used to evaluate activity from the colon to the 
small bowel [224],[225],[226],[201],[62],[227]. Studies have shown good correlation (r>0.8) 
with endoscopic disease activity in both CD and UC [228],[229].  One of the main drawbacks 
of indirect markers is their limited information on disease phenotype and potential 
complications.  
 
Statement 2.3.5.  ECCO-ESGAR Diagnostics GL (2018) 
Balloon-assisted enteroscopy can be used for diagnostic evaluation or endoscopic 
intervention (or both) throughout the small bowel [EL3] 
 
Balloon-assisted enteroscopy allows direct mucosal visualization of the entire small bowel. 
Unlike other imaging modalities, balloon-assisted enteroscopy also enables taking of biopsies, 
therapeutic intervention throughout the small bowel [286],[287],[288], and interventions to 
manage bleeding. One study showed a change in management in 75% of patients who 
underwent this investigation [289]. However, this examination is time consuming and 
requires patient sedation. The risk of perforation is 0.12% without therapeutic intervention 
but 1.74% with therapeutic intervention, the majority of which occurred after stricture 
dilatation [290]. Bleeding occurs in approximately 2.5% [291], although one series 
demonstrated four out of six significant bleeds occurring post polypectomy [292]. It is worth 
noting that real-world data on both the benefits and complications are skewed by selection 
bias, as at present this test is usually reserved for patients where other imaging modalities 
have been inconclusive or in scenarios when therapeutic intervention is a key aim.  
 
Statement 2.3.6. ECCO-ESGAR Diagnostics GL (2018) 
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Malabsorption parameters should be assessed at regular intervals in all patients with IBD 
[EL5]   
  
Nutritional deficiencies are frequently associated with symptomatic IBD. The reason for this 
is two-fold. Firstly, the discomfort and anorexia associated with disease flares preclude 
adequate intake. Secondly, inflammatory or fibrotic change to the bowel directly hinders 
absorption.  
 
In all patients with IBD, weight should be recorded at each clinic review with the aim of early 
dietetic support when unintentional weight loss is noted. Anaemia is common and should be 
screened for in all IBD patients; this topic is covered in full in chapter 1 of this guideline. 
Patients with symptoms suggestive of active disease should be screened for anaemia every 3 
months. Initial screening should include complete blood count, ferritin, and CRP. There is no 
evidence on optimal screening intervals for any of the parameters used for malabsorption. 
Common practice in patients with small-bowel disease or prior resection is to measure 
vitamin B12 and folic acid every 3 to 6 months. Judicious care must be taken when 
interpreting ferritin results in symptomatic patients; the ECCO anaemia guideline 
recommends ferritin values of up to 100 µg/L may still be consistent with iron deficiency in 
active disease, especially with a transferrin saturation of <20%. If low haemoglobin is 
confirmed, a more extensive workup should be undertaken as per the anaemia guideline.  
 
Low albumin is common in active IBD as it is an acute phase protein. Active IBD itself may lead 
to malabsorption, and low albumin in IBD may correlate with nutritional status. However, the 
use of albumin as a direct marker of malabsorption is tenuous. In a meta-analysis of 63 
studies, albumin did not correlate with nutritional status in calorie-restricted but otherwise 
healthy individuals [293]. Longitudinal follow up of serum albumin in patients with anorexia 
nervosa and in healthy controls also failed to yield significant differences [294]. As such, 
albumin is not an appropriate test for malabsorption and ECCO does not recommend albumin 
measurements for this reason.  
 
Low vitamin D has been observed in between 16 to 95% of IBD patients, depending upon the 
study [295],[296]. Deficiency is associated with active disease, female gender, and non-
Caucasian ethnicity, with one recent study suggesting higher prevalence in CD [297]. A 
retrospective analysis has also linked low vitamin D with more frequent flares and lower 
quality-of-life scores [298]. Unfortunately, prospective follow up after supplementation does 
not show a clear beneficial impact in disease course [299]. Nevertheless, ECCO suggests 
measuring vitamin D in symptomatic patients, then re-evaluating after treatment to verify 
that levels are replete.  
 
Other micronutrient deficiencies to be considered in IBD patients include vitamin K, selenium, 
vitamin A, vitamin C, zinc, vitamin B6, and vitamin B1 [300],[301]. All patients with 
symptomatic IBD do not routinely require evaluation of all of the above. However, testing 
should be considered in patients with small-bowel CD, in those who have undergone 
resection, and in those receiving nutritional supplementation (in particular parenteral 
nutrition) or if the specific clinical scenario lends suspicion to a deficiency (such as poor wound 
healing).  
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2.4 Imaging after surgery (including ileo-anal pouch) 
 
Statement 2.4.1. ECCO-ESGAR Diagnostics GL (2018) 
Ileocolonoscopy is the reference standard in the diagnosis of post-operative recurrence 
after ileocolonic resection. Endoscopy is recommended within the first 6 to 12 months after 
surgery [EL3] 
 
Statement 2.4.2. ECCO-ESGAR Diagnostics GL (2018) 
FC, IUS, MR enterography, and SBCE can be considered as noninvasive alternatives to detect 
postoperative recurrence, in particular after small-bowel resection [EL2] 
 
In the natural history of CD, intestinal resection is unavoidable in a significant proportion of 
patients. A majority of patients develop disease recurrence at or above the anastomosis and 
endoscopic recurrence precedes the development of clinical symptoms. Data from 
endoscopic follow up of patients after resection of ileocaecal disease have shown that in the 
absence of treatment, the post-operative endoscopic recurrence rate is approximately 65 to 
90% within 12 months and 80 to 100% within 3 years of the operation [302, 303]. The rates 
of recurrence are also significant in patients after total proctocolectomy and permanent 
ileostomy. In a recent meta-analysis of 18 cohort studies, the risk of clinical recurrence was 
28.0%, with a 5-year and 10-year median cumulative rate of 23.5% [304]. Identification and 
treatment of early mucosal recurrence may therefore prevent clinical recurrence. 
 
Ileocolonoscopy is the reference standard in the diagnosis of post-operative recurrence by 
defining the presence and severity of morphologic recurrence. Data from endoscopic follow 
up of patients after resection of ileocaecal disease have shown that in the absence of 
treatment, the post-operative recurrence rate is approximately 65 to 90% within 12 months 
[302, 303]. Ileocolonoscopy is therefore recommended within the first year after surgery 
where treatment decisions may be affected.   
 
Noninvasive modalities may also be accurate and efficient in detection of postoperative 
recurrence. 
 
FC can accurately identify postoperative recurrence [305, 306]. In a meta-analysis of ten 
studies that evaluated the accuracy of FC for detection of endoscopic recurrence, the pooled 
sensitivity and specificity values for assessing suspected endoscopic recurrence were 0.82 and 
0.61, respectively [307]. In a more recent prospective study, FC levels >100 μg/g indicated 
endoscopic recurrence (defined as Rutgeerts score ≥i2) with 89% sensitivity and 58% 
specificity and a NPV of 91%; the authors suggested that colonoscopy could have been 
avoided in 47% of patients. In an additional prospective study from the GETAID group, FC 
levels >100 μg/g were associated with a positive predictive value and NPV of 93% and 77%, 
respectively, for prediction of endoscopic recurrence [308]. 
  
Several imaging modalities are available to reliably diagnose postsurgical recurrence, 
including IUS, small-bowel follow through, CT enteroclysis or CT enterography including 
virtual colonoscopy, MR enteroclysis or MR enterography, SBCE, and white blood cell 
scintigraphy.   
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Several authors have previously emphasized the value of IUS in postoperative follow up and 
confirmed the observation of bowel wall thickening as an indicator for recurrence [309-311]. 
SICUS has shown an excellent correlation with the endoscopic Rutgeerts score (r=0.67; 
P=0.0001), reaching 87.5% accuracy for detecting CD recurrence [312]. SICUS is also 
considered to be superior to standard IUS in detecting postoperative CD recurrence after 
ileocaecal resection [313]. Bowel wall thickening was defined by thickness of >3.5 mm. SICUS 
prediction of recurrence was found to be correct in 100% of cases and confirmed by 
endoscopy [313]. In a recent retrospective series from Italy, the absolute incidence of new 
surgical intervention is 13% in patients with bowel thickness of 3 mm and 40% in patients with 
bowel thickness >6 mm [314]. 
 
CT enterography or CT enteroclysis are alternatives to endoscopy for assessing postoperative 
recurrence of CD activity [315]. In a prospective series that included 32 postoperative patients 
from China, a significant correlation between endoscopic and CT recurrence (r=0.782; 
P<0.0001) was demonstrated [316]. Due to false-negative findings, CT colonography has been 
tested for assessing the postoperative recurrence of CD with inconclusive results. However, 
CT colonography represents an alternative to conventional colonoscopy in noncompliant 
postsurgical patients with a rigid stenosis that does not allow passage of the endoscope [317]. 
However, due to concerns regarding cumulative radiation exposure, imaging modalities not 
associated with radiation (such as MR enterography or IUS) are preferable to CT 
enterography. 
 
MR enterography may be an alternative to endoscopy as a diagnostic tool in postoperative 
recurrence evaluation in CD patients. Similar to the endoscopic Rutgeerts score for assessing 
postoperative recurrence, one study showed an objective evaluation using an MRI-based 
index of activity and severity for postoperative recurrence. This score achieved a high 
correlation with the endoscopic index, which allowed differentiation between mild and 
severe lesions [318] and prediction of the risk of clinical postoperative recurrence in CD 
patients [319]. 
 
Although the Rutgeerts score has been used to evaluate the efficacy of several drugs, there is 
lack of information on whether mural healing changes seen by cross-sectional imaging 
techniques are in parallel to endoscopic MH. 
 
Capsule endoscopy can also be used to access postoperative recurrence [320, 321]. A fair 
correlation between the modalities (r2=0.54–0.64; P<0.05) was observed in a small pilot study 
that compared the Rutgeerts score calculated by capsule endoscopy and ileocolonoscopy 
[321]. An important advantage of capsule endoscopy is the ability to detect proximal small-
bowel recurrence. However, data on the use of capsule endoscopy for this indication is 
currently very limited, and patency capsule evaluation should be recommended prior to 
capsule endoscopy to minimize the risk of retention. 
 
In a recent meta-analysis, MR enterography, IUS, and SBCE had excellent accuracy (area under 
the curve >0.9 for all modalities) for detection of endoscopic recurrence as defined by a 
Rutgeerts score ≥2 [322]. 
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Statement 2.4.3. ECCO-ESGAR Diagnostics GL (2018) 
Endoscopy with biopsies should be performed in the assessment of pouch-related 
symptoms [EL2] 
 
The ileo-anal pouch is a well-established option for patients who require surgery for chronic 
UC. Despite excellent functional results, the short-term and long-term outcome of ileal pouch 
with anal anastomosis (IPAA) are determined by the occurrence of complications. These may 
be directly related to the surgery or may occur over the long term. Immediate postoperative 
complications include leakage, abscess formation, pelvic sepsis, and fistula formation. More 
chronic disorders following IPAA are pouchitis, cuffitis, irritable pouch syndrome, pouch 
stricture, pouch sinus, afferent loop syndrome, or small-bowel obstruction [323]. Following 
surgery, up to 40% of patients have a single episode of pouchitis (a nonspecific inflammatory 
condition at the ileal pouch reservoir) [324] within 12 months, whereas 19% and 5% 
experience intermittent episodes and chronic pouchitis, respectively [325-327]. The incidence 
of pouch failure is up to 7% at 3 years and 9% at 5 years [328, 329].  
 
Endoscopy plays a significant role in diagnosing and guiding therapy in patients with pouch 
complications [323, 330-333]. Importantly, the severity of symptoms does not always 
correlate with endoscopic or histological findings [334, 335]. Therefore, a cumulative clinical, 
endoscopic, and histological assessment is needed. Several diagnostic criteria are available 
and the most common in clinical use is the pouch disease activity index [336]. Furthermore, 
it is valuable to classify the phenotype of pouchitis before initiating therapy to provide 
guidance regarding treatment modalities and duration of treatment [337]. In case of 
antibiotic-refractory pouchitis, endoscopic evaluation can facilitate exclusion of contributory 
factors such as ischaemic pouchitis and infections [338]. Pouch endoscopy is essential in the 
diagnosis of CD of the pouch and prepouch ileitis [323, 333, 334].  
 
FC levels are significantly elevated in cases of pouchitis. In a study that included 56 pouch 
patients, FC concentrations correlated closely with the objective pouchitis score, the pouch 
disease activity index, and endoscopic and histologic inflammatory scores (Spearman rank 
test, P-values <0.0001); FC levels ≥92.5 µg/g had a sensitivity of 90% and a specificity of 76.5% 
for detection of pouch inflammation [339]. Other potential biomarkers of pouch 
inflammation, such as faecal matrix metalloprotease-9 [340] and serum alpha-1 antitrypsin 
[341], are also being evaluated but are currently not in routine clinical practice. 
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Chapter 3 Detection of complications 
 
3.1 Detection of strictures 
 
Statement 3.1.1. ECCO-ESGAR Diagnostics GL (2018) 
Cross-sectional imaging should be used to detect small-bowel strictures [EL2]. Due to 
radiation exposure with CT, the preferred methods are MRI, intestinal ultrasound (IUS), or 
both. No imaging technique is currently able to determine the degree of fibrosis [EL3] 
 
Despite wide heterogeneity in the definitions for strictures, the accuracy of intestinal 
ultrasound (IUS), CT enterography, and MR enterography is high for diagnosis of stenosis 
affecting the small bowel [81]. IUS is an accurate technique for detection of small-bowel 
stenosis. Based on pooled data using surgery as a reference standard, the sensitivity and 
specificity of IUS is 79% and 92%, respectively [81]. Use of oral contrast agents, such as small 
intestine contrast ultrasound (SICUS), can improve the accuracy of IUS in detecting the 
presence and number of small-bowel stenosis; sensitivity increased from 74 to 89% in one 
study [130]. The sensitivity of CT enterography for stenosis detection was 92% and specificity 
was 100% when CT was compared with ileocolonoscopy [342] [343, 344]. Studies using 
endoscopy and surgery as a reference standard reported a sensitivity of 85% and 90%, 
respectively, with a specificity of 100% [82, 345]. MRI studies with an adequate reference 
standard (endoscopy, surgery, or both) for diagnosis of stenosis showed a sensitivity of 89% 
and a specificity of 94% [81]. The accuracy had a tendency to improve using enteroclysis (i.e. 
enteric contrast introduced via nasojejunal intubation rather than oral) as compared to 
enterography (sensitivity of 100% versus 86% and specificity of 100% versus 93%, 
respectively) [252]. Direct comparison of CT and MRI for diagnosis of stenosis indicated a 
similar sensitivity (85% versus 92%) and specificity (100% versus 90%) [82]. The use of luminal 
contrast and anti-peristaltic agents is recommended for CT enterography  and MR 
enterography [346]. 
 
Strictures in Crohn’s disease (CD) are transmural and contain variable proportions of 
inflammatory and fibrotic tissue [347]. Quantification of active inflammation versus fibrosis 
is challenging. With regards to current techniques used in clinical practice, no technique is 
sufficiently accurate to assess the degree of fibrosis in a stricture with adequate precision to 
guide clinical decisions. While the stratified echo pattern of the different layers of the 
intestinal wall components of a stricture has been associated with collagen deposition, this 
approach lacks consistency [348]. On CT enterography, the presence of fibrosis was linked to 
stenotic lesions, but could not distinguish inflammation from fibrosis [349]. Conventional-
sequence MR enterography revealed conflicting results for fibrosis characterization [350, 
351]. Rimola et al. developed a technique using gadolinium enhancement between 70 
seconds and 7 minutes on MR enterography. This approach was able to distinguish mild or 
moderate fibrosis from severe fibrosis irrespective of the degree of inflammation [352]. This 
approach awaits external validation.  
 
Although several novel imaging techniques have been proposed, data are limited, acquisition 
methods are unstandardized, and there is limited evidence to support external validity. These 
techniques include MR with dynamic contrast-enhanced technique [353], magnetization-
transfer MR [354, 355], ultrasound elastography [356, 357], or contrast-enhanced ultrasound 
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(CEUS) [358, 359]. While stenosis can be detected by endoscopy, most investigators use the 
ability to pass the endoscope as a measure of stenosis. The proportion of fibrosis cannot be 
evaluated precisely by biomarkers, endoscopy, or histology. There is no consistent approach 
regarding strategy for monitoring strictures over time and with which method.  
 
While not the preferred technique, ileocolonoscopy can be used for stricture diagnosis. The 
commonly used definition is a narrowing that cannot be passed with an endoscope [360]. An 
ileocolonoscopy is not necessary in all cases after a stricture has been detected on cross-
sectional imaging, but should be considered if endoscopic therapy through endoscopic 
balloon dilatation is a valid therapeutic approach [361] and in case of colonic strictures when 
malignancy cannot be excluded. 
 
Statement 3.1.2. ECCO-ESGAR Diagnostics GL (2018) 
Any colonic stricture should be carefully surveyed due to risk of carcinoma [EL4]; surgery 
should be considered 
 
Consistent with the observation that patients with ulcerative colitis (UC) and patients with 
colonic CD are at an increased risk of developing colorectal cancer (CRC) [362-364], detection 
of a new colonic stricture should lead to a careful diagnostic workup to exclude malignancy. 
A recently published population-based study suggested that colonic strictures at diagnosis or 
during follow up are associated with a 3.6% and 4.9% probability of CRC at 5 and 10 years, 
respectively [365]. According to the ECCO evidence-based consensus for endoscopy in IBD, 
patients with strictures detected within 5 years should be considered ‘high risk’ and receive 
surveillance colonoscopy yearly. Malignancy is more frequent in the CD-affected colon and 
the incidence is comparable to UC [366, 367]. In a GETAID study, dysplasia or cancer was 
detected in 3.5% of patients with IBD who underwent surgery for colonic strictures [368]. In 
addition, small-bowel adenocarcinoma is rare but can be fatal if overlooked [369]. The 
endoscopist should therefore have a low threshold for taking a biopsy before endoscopic 
balloon dilatation [369]. In addition, the use of paediatric endoscopes with a smaller diameter 
may permit stricture traversal. Cross-sectional imaging should be considered as a 
complementary diagnostic modality. Currently, there is no method (including histology) that 
can definitively rule out malignancy in a patient with IBD and colonic strictures.       
 
 
3.2 Detection of fistulae and abscesses 
 
3.2.1 Detection of intra-abdominal fistulae and abscesses 
 
Satement 3.2.1.1. ECCO-ESGAR Diagnostics GL (2018) 
Cross-sectional imaging (IUS, MRI, and CT) can detect internal penetrating disease and intra-
abdominal abscesses with varying accuracy [EL1]. MRI is preferable to ultrasound for deep-
seated fistulae or abscesses or pelvic fistulae or abscesses [EL4] 
 
In a systematic review for the diagnosis of intra-abdominal fistulizing lesions, cross-sectional 
imaging showed the following accuracy: for CT with surgery and endoscopy as reference 
standard, the sensitivity was 70% and specificity 97%; MRI with surgery or endoscopy as the 
reference standard showed a sensitivity of 76% and specificity of 96% for fistulae diagnosis; 
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IUS with surgery, barium studies, and colonoscopy as the reference standard showed a 
sensitivity of 74% and specificity of 95% [81]. Oral contrast agents do not improve accuracy 
of IUS for detection of internal fistulae [130]. If available, CT or MRI are preferable for 
detection of intra-abdominal or pelvic fistulae over ultrasound; MRI has the advantage of no 
radiation exposure [80, 81]. Cross-sectional imaging has a pivotal role in the assessment of 
penetrating complications of CD. In one study, there was no clinical fistula or abscess 
suspicion from pre-CT examination in half of patients with penetrating CD complications. 
Cross-sectional imaging changed management in more than three quarters of these patients 
[370]. White blood cell scintigraphy is not indicated for diagnosis and characterization of 
fistulae. 
 
A systematic review revealed the following point estimates for diagnosis of abscesses: using 
surgery as a reference standard, IUS had a sensitivity of 84% and a specificity of 93%, which 
was dependent on disease location in CD [81]. Detection of intra-abdominal abscesses via CT 
with surgery as the reference standard revealed a sensitivity of 86% and a specificity of 88% 
[349]. One prospective study showed a sensitivity of 85% and specificity of 95% of CT for intra-
abdominal abscesses [371]. CT and ultrasound showed an overall high and comparable 
accuracy in the detection of intra-abdominal abscesses, although CT showed a slightly greater 
positive predictive value than ultrasound. CEUS has been shown to differentiate between an 
intra-abdominal phlegmon and abscess with high accuracy [372]. The accuracy of MRI for 
abscess detection using surgery as the reference standard showed sensitivities ranging from 
86 to 100% and specificities from 93 to 100% [351, 373, 374]. A systematic review of these 
three studies showed a sensitivity of 86% and a specificity of 93% for MRI detection of 
abscesses [81]. Endoscopy is not used for evaluation of internal penetrating disease due to an 
inability to image extramural structures. 
  
 
3.2.2 Detection of perianal fistulae and abscesses 
 
Statement 3.2.2.1. ECCO-ESGAR Diagnostics GL (2018) 
MRI is the most accurate imaging modality for diagnosis and classification of perianal CD 
and is the recommended first-line test [EL1]. Transrectal ultrasonography (TRUS) is superior 
to clinical examination and is an alternative to MRI [EL2]. Combining any modality of MRI, 
examination under anaesthesia (EUA), or TRUS improves accuracy [EL2] 
 
Statement 3.2.2.2.  ECCO-ESGAR Diagnostics GL (2018) 
EUA with drainage is recommended if a perianal abscess is suspected and should not be 
postponed if pelvic imaging is not immediately available [EL2] 
 
Statement 3.2.2.3. ECCO-ESGAR Diagnostics GL (2018) 
Endoscopic evaluation of the rectum is essential to determine the most appropriate 
management strategy for perianal CD [EL2] 
 
Three diagnostic tests are commonly used alone or in combination for the diagnosis and 
classification of perianal disease, namely examination under anaesthesia (EUA), MRI, or 
transrectal ultrasonography (TRUS). Both TRUS (with and without hydrogen peroxide) and 
MRI can identify and classify fistulous tracts with a diagnostic accuracy for MRI ranging from 
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80 to 100% in most reported studies. The diagnostic accuracy of TRUS is more variable and 
ranges from 50 to 100% [163, 168, 375-384]. MRI the recommended first-line test, as TRUS is 
hindered by patient discomfort, cannot be performed in the presence of stenosis, and has a 
smaller field of view. EUA by an experienced surgeon has long been considered the reference 
standard for assessment of perianal CD. However, a prospective blinded study comparing 
EUA, MRI, and TRUS found diagnostic accuracies of 91%, 87%, and 91%, respectively, with 
100% accuracy when any two of the tests were combined [167]. A larger prospective clinical 
trial compared preoperative digital rectal examination (33% sensitivity), TRUS (75% 
sensitivity), and body-coil MRI (85% sensitivity). MRI may change management in patients 
with perianal CD by detecting abscess not suspected clinically [375, 385] and should therefore 
precede EUA unless there is a need for immediate drainage of sepsis. Although the use of EUA 
may be limited by luminal stenosis, dilatations during the procedure can be performed. 
 
Undiagnosed fistula extensions and abscesses are major causes of recurrent disease after 
attempted surgical cure [376]. Furthermore, full knowledge of the presence and extent of 
these secondary tracts is required for appropriate medical therapy, particularly with anti-TNF 
agents [164]. Accurate classification of perianal fistulae is thus essential prior to starting 
therapy. Two prospective studies evaluated the effect of preoperative MRI on clinical 
outcome after surgical treatment for perianal fistulizing disease [375, 376]. Both studies 
showed that MRI revealed additional and clinically relevant information to the surgeon 
performing EUA. A prospective comparison of modalities using a robust outcome-based 
reference standard found MRI superior to TRUS for fistula classification and detecting 
abscesses [168]. In general, MRI is preferred in CD, especially in recurrent or suspected 
complex disease. 
 
Endoscopy can facilitate detection of perianal disease and has a role in assessing the degree 
of inflammation in the rectum, which may affect management [104]. Endoscopy has not been 
shown to be useful in monitoring perianal disease or assessing response to fistula therapy. 
Transperineal ultrasound (TPUS) has been evaluated in small studies for the documentation 
of perianal disease and may have clinical utility [386, 387]. 
 
3.3 Detection of pouch complications 
 
Statement 3.3.1. ECCO-ESGAR Diagnostics GL (2018) 
Cross-sectional imaging and endoscopy are complementary methods for assessing 
suspected structural complications after ileal pouch anal anastomosis (IPAA) [EL4]. 
Pouchography can be used additionally to assess functional disorders and other 
complications [EL3] 
 
Inflammatory and noninflammatory complications of the ileal pouch anal anastomosis (IPAA) 
are common and include strictures, abscesses, fistulae, and sinus tracts culminating in pouch 
failure in up to 9% of cases at 5 years [328, 329, 331, 388]. These complications can be 
immediate postoperative or long-term. In the case of IPAA stenosis, fistulae, abscesses, and 
sinuses, EUA by an experienced IBD surgeon is important for diagnosis and timely treatment 
of most pathologies. The choice of diagnostic modality depends on the clinically suspected 
disorder, local expertise, and availability. Endoscopy is essential to obtain information on 
mucosal status and for diagnosis of intraluminal or anastomotic complications, such as 
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strictures. Endoscopic balloon dilatation can be used to treat pouch stricture [389, 390].  for 
suspected extraluminal complications, such as abscesses, fistulae, or sinus tracts [391, 392]. 
Pelvic CT, MRI, and TRUS or TPUS are sensitive methods that allow the identification and 
characterization of septic problems [168]; use of these modalities depends on local availability 
and experience level. Unfortunately, the proportion of fibrosis versus inflammation cannot 
be assessed precisely by any currently available diagnostic tool [393-395]. Contrast 
pouchography can assist in assessment of pouch strictures, pouch fistulae, and leakage [99] 
but is only used in limited number of centres. A correlation of pelvic CT, MRI, pouch 
endoscopy, and retrograde pouchography findings with clinical outcome revealed a 
reasonable accuracy for diagnosis of strictures, fistulae, sinuses, and pouch leaks with all 
methods [396]. CT had the lowest accuracy for small-bowel strictures (74%); MRI had the 
lowest accuracy for pouch sinuses (68%). A combination of two imaging tests increased 
diagnostic accuracy to 100%. In the acute post-operative setting, complications of IPAA 
include anastomotic leaks and abscesses. Leaks from the tip of the J-pouch and the pouch-
anal anastomosis often result in pelvic abscesses. Detection of anastomotic dehiscence after 
IPAA is possible using transanal ultrasound and TPUS, although pelvic CT or MRI scanning is 
usually required to outline the full extent of the complication and guide drainage [395, 397]. 
Complications of the pouch should be discussed in a multidisciplinary team setting to 
individualize management.  
 
 
3.4 Detection of emergency complications  
 
Statement 3.4.1. ECCO-ESGAR Diagnostics GL (2018) 
In acute severe colitis a plain abdominal radiograph is an acceptable first study to detect 
toxic megacolon. In selected cases, CT could be indicated as an initial method to screen for 
complications [EL3] 
 
Diagnosis of toxic megacolon is usually made by clinical signs of systemic toxicity supported 
by imaging confirmation. Detection of transverse colonic dilatation >5.5 cm by means of plain 
abdominal X-ray is still the most established radiological definition of toxic megacolon [398]. 
Some case series have shown that in patients with toxic megacolon, CT scan and IUS can be 
promising alternatives that provide additional information [399, 400].  A CT scan is an 
important tool for diagnosis of associated perforation or ascending pylephlebitis. A study 
observed that among 18 patients with toxic megacolon (4 with underlying UC), CT scans 
revealed abdominal complications in four patients missed clinically and on plain abdominal 
films [399]. Larger clinical studies are warranted to assess the diagnostic benefit of cross-
sectional radiological studies in the assessment of toxic megacolon. 
 
Statement 3.4.2. ECCO-ESGAR Diagnostics GL (2018) 
When a perforation is suspected, CT should be performed in all patients with acute 
abdominal pain and established diagnosis of IBD [EL2] 
 
Spontaneous free perforation is a rare but serious event in CD but can be more common in 
acute severe colitis. Spontaneous free perforation may result from severe inflammation or 
superimposed malignancy. It is estimated that approximately 1 to 2% of patients with CD will 
present with a free perforation initially or sometime over their disease course [401, 402]. 
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In IBD patients, intestinal perforation frequently presents as a peri-intestinal abscess that may 
be detected by cross-sectional imaging methods such as IUS, MRI, or CT. A systematic review 
showed that in this context the three techniques have a high accuracy for identification of 
fistulae, abscesses, and stenoses (sensitivities and specificities of 0.80), although IUS yields 
more false-positive results for abscesses [81]. 
 
3.5 Detection of postoperative complications 
 
Statement 3.5.1. ECCO-ESGAR Diagnostics GL (2018) 
Acute postoperative complications in IBD patients (mainly anastomotic leaks and 
abscesses) should be initially investigated by CT [EL3]. Ultrasound may be an alternative 
first-line investigation, but should be followed by immediate CT, if negative or equivocal. 
[EL4] 
 
Anastomotic leaks after intestinal surgery may be promptly diagnosed clinically due to specific 
clinical presentation in the postoperative period. However, when anastomotic leaks are 
suspected in cases of atypical clinical manifestations, correct and rapid radiological diagnosis 
is necessary for successful management. Few studies have been designed to assess detection 
of these complications in CD [81] and most are derived from the surgical literature [403-405]. 
A prospective database populated over a 10-year period showed that anastomotic leaks are 
frequently diagnosed late in the postoperative period and often after initial hospital discharge 
(median time 12.7 days, range 1–38) [403]. In this study, CT was the preferred imaging 
modality [403]. In contrast, other studies showed that most postoperative CT features overlap 
between patients with or without clinically important anastomotic leaks and that CT studies 
performed on patients shortly after abdominal surgery are not definitive. A negative CT does 
not exclude postoperative lower gastrointestinal tract leaks [404, 405]. A combination of CT, 
laboratory examinations, and clinical signs and symptoms will optimize diagnosis of such 
complications. 
 
There is no evidence that the addition of intraluminal contrast is more sensitive for detection 
of anastomotic dehiscences in IBD, as peri-anastomotic located fluid-containing gas is the 
most prevalent sign of anastomotic insufficiency [405]. Selected use of intraluminal contrast 
can be individualized according to physician preference. 
 
3.6 Surveillance for colorectal cancer in ulcerative colitis 
Risk of colorectal cancer in ulcerative colitis 
 
Statement 3.6.1. ECCO-ESGAR Diagnostics GL (2018) 
(ECCO statement 8D [adapted from statement 13D in Annese et al.13]) 
Screening colonoscopy should be offered 8 years after onset of symptoms to all patients to 
reassess disease extent and exclude dysplasia [EL5] 
 
Statement 3.6.2. ECCO-ESGAR Diagnostics GL (2018) 
(ECCO statement 8E) 
When disease activity is limited to the rectum without evidence of previous or current 
endoscopic or microscopic inflammation (or both) proximal to the rectum, inclusion in a 
regular surveillance colonoscopy program is not necessary [EL2] 
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Statement 3.6.3. ECCO-ESGAR Diagnostics GL (2018) 
(ECCO statement 8F) 
In patients with concurrent primary sclerosing cholangitis (PSC), annual surveillance 
colonoscopy should be performed following the diagnosis of PSC, irrespective of disease 
activity, extent, and duration [EL3] 
 
Statement 3.6.4. ECCO-ESGAR Diagnostics GL (2018) 
(ECCO statement 8G [adapted from statement 13E in Annese et al.13]) 
Ongoing surveillance should be performed in all patients apart from those with proctitis 
[EL3]. Patients with high-risk features (e.g. stricture or dysplasia detected within the past 5 
years, PSC, extensive colitis with severe active inflammation) should have their next 
surveillance colonoscopy scheduled for 1 year [EL4]. Patients with intermediate risk factors 
should have their next surveillance scheduled for 2 to 3 years. Intermediate risk factors 
include extensive colitis with mild or moderate active inflammation, post-inflammatory 
polyps, or a family history of colorectal cancer (CRC) in a first-degree relative diagnosed at 
age 50 years and above [EL5]. Patients with neither intermediate nor high-risk features 
should have their next surveillance colonoscopy scheduled for 5 years [EL5] 
 
Statement 3.6.5. ECCO-ESGAR Diagnostics GL (2018) 
(ECCO statement 8H) 
Colonoscopic surveillance is best performed when ulcerative colitis (UC) is in remission, 
because it is otherwise difficult to discriminate between dysplasia and inflammation on 
mucosal biopsies [EL5] 
 
Statement 3.6.6. ECCO-ESGAR Diagnostics GL (2018) 
Surveillance colonoscopy should take into account local expertise. Chromoendoscopy with 
targeted biopsies has been shown to increase dysplasia detection rate [EL2]. White-light 
endoscopy is less accurate. If white-light endoscopy is used, random biopsies (quadrantic 
biopsies every 10 cm) and targeted biopsies of any visible lesion should be performed [EL3]. 
High-definition endoscopy should be used if available [EL2] 
 
Statement 3.6.7. ECCO-ESGAR Diagnostics GL (2018) 
Where dysplasia of any grade is found without an associated endoscopically visible lesion, 
urgent repeat chromoendoscopy should be performed by an experienced endoscopist to 
determine whether a well-circumscribed lesion exists and to assess for synchronous 
dysplasia [EL5]. 
A patient with confirmed low-grade dysplasia detected in mucosa without an associated 
endoscopically visible lesion should undergo repeat chromoendoscopic colonoscopy with 
additional random biopsies within 3 months [EL5] 
 
Statement 3.6.8. ECCO-ESGAR Diagnostics GL (2018) 
(ECCO statement 8K) 
Presence of low-grade or high-grade dysplasia should be confirmed by an independent 
gastrointestinal specialist pathologist [EL5] 
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Longstanding UC and CD are associated with an increased risk of CRC with a variable estimate 
between studies [362, 363] [364]. However, the risk of CRC seems to decline over time [406-
408]. Possible reasons are the emergence of effective surveillance strategies, better control 
of inflammation with drugs, and a modified approach to maintenance therapy or colectomy, 
as stated in previous guidelines [409]. 
 
On the basis of systematic endoscopic assessment, together with medical and family history 
of the patient, surveillance colonoscopy programs have been developed to reduce CRC-
associated morbidity and mortality [362]. At the onset of these programs, an initial screening 
colonoscopy is performed to reassess disease extent and confirm the absence of dysplastic 
lesions [362]. The timing of surveillance colonoscopies should be based on the level of risk of 
the patient, as extensively discussed in the recent ECCO consensus on UC [362] (Table x). The 
suggested timeline for surveillance in Crohn’s colitis is also listed in Table 2. 
 
 
 
Table x. Timeline of endoscopic surveillance according to risk factors after screening 
colonoscopy 
         Risk 
level 
Risk factors Surveillance  
Lower risk Extensive colitis with mild endoscopic or histological 
inflammation  
Colitis affecting <50% of the colon 
 Every 5 years 
Intermediate 
risk 
Extensive colitis with mild endoscopic or histologic 
inflammation (or both) 
CRC in a first-degree relative older than 50 years 
Every 2–3 
years 
Higher risk Extensive colitis with moderate-to-severe endoscopic or 
histologic inflammation (or both) 
CRC in a first-degree relative younger than 50 years 
History of PSC (included post-OLT) 
Stricture in past 5  years  
Dysplasia in the past 5 years in a patient who declines 
surgery 
Yearly 
CRC, colorectal cancer; PSC, primary sclerosing cholangitis; OLT, orthoptic liver 
transplantation 
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Good bowel preparation is essential for an efficient surveillance colonoscopy, since the 
quality of the preparation in UC patients significantly affects the lesion detection rate [410].  
A recent colitis surveillance study demonstrated that high-definition colonoscopy improves 
dysplasia detection in comparison to standard definition [362, 411]. Targeted biopsies have 
been shown to be noninferior to random biopsies for neoplasia detection rate per 
colonoscopy in a randomized controlled trial [362, 412]. Spraying dyes, such as methylene 
blue or indigo carmine [413-415], highlight subtle changes in the colonic mucosa architecture 
and can improve the detection rate of dysplasia [416]. There is abundant evidence from 
clinical trials and real-life studies that chromoendoscopy is superior to white-light endoscopy 
for dysplasia detection [417-419] [420] [421-425], independent of operator familiarity or from 
the availability of high-resolution endoscopy. Narrow-band imaging and endomicroscopy 
cannot currently be recommended for dysplasia screening in IBD [362].  
 
3.7 Diagnostic and monitoring techniques during pregnancy 
 
Statement 3.7.1. ECCO-ESGAR Diagnostics GL (2018) 
IUS and abdominal MRI without intravenous gadolinium are the safest techniques to 
examine pregnant women in whom IBD is known or suspected, regardless of the trimester 
[EL5] 
 
Statement 3.7.2. ECCO-ESGAR Diagnostics GL (2018) 
Endoscopy is generally considered to be safe in pregnancy; however, procedures should 
only be performed when there is a strong indication and clear clinical benefit [EL3] 
 
Data are scarce concerning the medical imaging of pregnant women in whom IBD is known 
or suspected. Recent guidelines by the American College of Obstetricians and Gynecologists 
state that ultrasound, MRI, CT, and nuclear medicine imaging techniques are theoretically 
safe if used prudently [426]. The main concerns regarding these techniques are increased 
foetal temperature caused by application of high-frequency ultrasound or a magnetic field 
and foetal radiation exposure, either via X-ray or radioisotopes.  
 
Ultrasound and MRI are the best choice for pregnant women, but application of either can 
theoretically increase the temperature of maternal and foetal tissues [427, 428]. The Food 
and Drug Administration limits the spatial-peak temporal average intensity of ultrasound 
transducers to 720 mW/cm2 [426]. Ultrasound examination should be performed according 
to the ‘As Low As Reasonably Achievable’ principle [429], accounting for exposure time 
related to the thermal index generated during the procedure (keeping this value <1) [430] 
[431]. No specific data apply to IBD populations.   
 
Regarding MRI, a recent retrospective survey of 1 424 105 deliveries from the province of 
Ontario compared those with first-trimester MRI (n=1737) to no MRI (n=1 418 451). MRI did 
not confer additional risk of congenital anomalies, neoplasms, or vision or hearing loss. No 
additional risk of nephrogenic systemic fibrosis was found when gadolinium-enhanced MRI 
(n=397) was compared with no MRI (n=1 418 451). Gadolinium-enhanced MRI at any time 
during pregnancy was associated with an increased risk of a broad set of rheumatologic, 
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inflammatory, or infiltrative skin conditions (adjusted hazard ratio 1.36; 95% CI 1.09–1.69) 
and for stillbirth or neonatal death (adjusted relative risk 3.70; 95% CI 1.55–0.85) [432]. 
Another retrospective study of 751 neonates exposed to 1.5T MRI in utero compared with 
10 042 unexposed neonates found no difference between groups regarding birth weight or 
incidence of hearing impairment or deafness [433].  
 
Specific data on MRI in pregnant women with IBD are limited. Stern et al. reported nine 
pregnant women (7 with established CD) who underwent unenhanced MRI. Features typical 
of active CD were identified with their protocol (mural thickening ≥3 mm, ulcers, mural 
oedema, ‘comb sign’, phlegmon, abscesses, and fistulae). MRI detected complications in 
four women and was sufficiently accurate to inform medical management [434]. One case 
report described MR colonography used safely to examine a pregnant woman of 20 weeks 
gestational age with acute severe colitis, indicating conservative therapy that avoided 
colectomy [435]. Another case report described a pregnant woman of 26 weeks gestational 
age who underwent unenhanced MRI to diagnose adhesions following ileo-anal pouch, with 
no adverse events [436]. Another case report did not reveal any safety concerns in a 
pregnant woman with fistulizing CD [437].  
 
X-ray exposure is associated with an increased risk of congenital malformation [438, 439] 
and childhood cancer [440], estimated at 6% per Gy [439]. However, exposure at ≤50 mGy is 
considered safe at any trimester [439]. In the absence of data for IBD patients, Hurwitz et al. 
showed that multidetector row CT to investigate suspected appendicitis conferred a dose of 
1.52 to 1.68 cGy and 2 to 4 cGy at months 0 and 3, respectively [441]. Unless potential risks 
are outweighed by clinical need, current data do not support the use of CT or any other X-
ray technique. Due to the absence of specific data regarding use of radioisotopes in 
pregnant women with suspected or diagnosed IBD, radioisotopes should be avoided in this 
patient population.  
 
Limited evidence exists regarding the utility and safety of endoscopy in pregnant women 
with IBD. Due to potential complications described in the recent ECCO pregnancy and 
reproduction consensus [442], endoscopy in pregnancy should be reserved for strong 
indications. To avoid vena cava compression, pregnant patients should be placed in the left 
pelvic tilt or left lateral position before, during, and after the endoscopic procedure. Close 
attention should be paid to appropriate drug selection, using drugs appropriate for 
pregnancy and using the minimum dose possible to achieve the desired effect. Sedative 
drugs should be administered to provide patient comfort; oversedation should be avoided. 
 
3.8. Diagnostics for biliary extra-intestinal manifestations of IBD 
 
Statement 3.8.1. ECCO-ESGAR Diagnostics GL (2018) 
Ultrasound is the first-line noninvasive imaging procedure in the workup of elevated liver 
enzymes, cholestasis, or both [EL1]. Magnetic resonance cholangiopancreatography 
should be considered if ultrasound and serology are inconclusive [EL1] 
 
Statement 3.8.2. ECCO-ESGAR Diagnostics GL (2018) 
(ECCO EIM Guidelines: statement 7B in M. Habord et al.16) 
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If high-quality magnetic resonance cholangiography is normal in a patient with IBD and 
suspected PSC, an ultrasound-guided liver biopsy should be considered to diagnose small-
duct PSC [EL2] 
 
Statement 3.8.3. ECCO-ESGAR Diagnostics GL (2018) 
(ECCO EIM Guidelines: statement 7H in M. Habord et al.16) 
There is no evidence-based follow up regimen proven to detect biliary neoplasia earlier in 
PSC. Annual ultrasonography to detect gallbladder mass lesions is recommended [EL4]. 
Additional imaging (MRI/MRC, CT, or endoscopic retrograde cholangiography [ERC]) 
should be performed without delay if cholangiocarcinoma is suspected [EL1] 
 
Statement 3.8.4. ECCO-ESGAR Diagnostics GL (2018) 
(ECCO EIM Guidelines: statement 7E in M. Habord et al.16) 
In PSC patients with clinical or radiological suspicion of significant strictures or 
cholangiocarcinoma, ERC is recommended to diagnose strictures that may be amenable to 
endoscopic dilatation (with or without stenting) and for brush cytology specimen 
evaluation [EL2]. Prophylactic antibiotic therapy is recommended [EL1] 
 
The statements above have been included in this ECCO diagnostic guideline for completion 
of endoscopic or cross-sectional imaging diagnostics of extra-intestinal biliary involvement 
in patients with IBD. For detailed explanation and references please refer to the ECCO EIM 
guideline. 
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